farnesol profile

Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Products

Flora	Rank	Flora Definition	Family	Family Definition
Cyclamen	genus	A plant genus of the family PRIMULACEAE that contains triterpenoid saponins.[MeSH]	Primulaceae	A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH]
Citronella	genus	[no description available]	Cardiopteridaceae	[no description available]

ID Source	ID
PubMed CID	445070
CHEMBL ID	25308
CHEBI ID	28600
CHEBI ID	16619
CHEBI ID	26199
SCHEMBL ID	58068
MeSH ID	M0008233

Synonym
AC-422
3,7,11-trimethyl-2,6,10-dodecatrienol
CHEBI:28600
3,7,11-trimethyldodeca-2,6,10-trien-1-ol ,
LS-14447
CHEBI:16619 ,
(2-trans,6-trans)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
trans,trans-alpha-farnesol
all-trans-farnesol
trans,trans-farnesol ,
(e)-farnesol
(e,e)-farnesol
(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
(2-trans,6-trans)-farnesol
.beta.-farnesol
SPECTRUM5_002027
fema no. 2478
trimethyl dodecatrienol
ai3-44561
hsdb 445
einecs 225-004-1
epa pesticide chemical code 128911
nsc 60597
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, (e,e)-
BSPBIO_002660
inchi=1/c15h26o/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16h,5-6,8,10,12h2,1-4h3/b14-9+,15-11
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, (2e,6e)-
(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
farnesol (6ci)
fci 119a
fof ,
3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl- (8ci,9ci)
2-trans,6-trans-farnesol
trans-farnesol
(2e,6e)-farnesol
106-28-5
C01126
4602-84-0
farnesol
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-
farnesol, 95%
bdbm11021
trans,trans-farnesol, 96%
NCGC00095654-01
NCGC00095654-03
NCGC00095654-02
NCGC00095654-04
SPECTRUM1501022
NCGC00095654-05
(e,e,)-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
all-trans farnesol
2-trans-s-6-trans-farnesol
(e,e,)-farnesol
LMPR0103010001
2e,6e-farnesol
A2865747-EC66-4B9C-A593-0A066A438904
CHEMBL25308
T0608
A801411
AKOS004907430
2,6-di-trans-farnesol
inhibitor a2
unii-x23pi60r17
x23pi60r17 ,
tox21_302034
NCGC00255293-01
cas-4602-84-0
dtxcid80196591
ST072172
(2e,6e)-3,7,11-trimethyl-dodeca-2,6,10-trien-1-ol
CCG-38862
unii-eb41qiu6jl
eb41qiu6jl ,
STL372743
all-e-farnesol
(e,e)-3,7,11-trimethyl-2,6,10-dodecatnen-1-ol
farnesol trans,trans-farnesol [mi]
farnesol, (2e,6e)-
3,7,11-trimethyldodeca-2-trans,6-trans,10-trien-1-ol
(e)-.beta.-farnesol
fema no. 2478, (2e,6e)-
S4941
BRD-K24656285-001-01-0
SCHEMBL58068
(2e, 6e)-3,7,11-trimethyl2,6,10-dodecatrien-1-ol
2e,6e-farnesyl alcohol
e,e-farnesol
trans,trans farnesol
(e,e)farnesol
trans- farnesol
transfarnesol
BBL027412
cis-trans-farnesol
Q-201851
CHEBI:26199
farnesol, (e,e)-
farnesol (2e,6e)
farnesol, trans, trans
W-109985
trans,trans-farnesol; trans-farnesol
DTXSID2040789
mfcd00002918
trans,trans-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
(e,e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
F1905-7040
trans,trans-farnesol, analytical standard
farnesol, analytical standard
nikkosome
trans, trans-farnesol
trans,trans-farnesol, 97%
HY-Y0248A
CS-0031456
BCP22704
Q420449
AS-16107
AMY33538
(e,)-arnesol
trans,trans-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol, (e,e)-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
EN300-1692687
Z2315575130

Excerpt	Reference	Relevance
"03 mg/kg/day group, ther were no toxic signs."	( [A 13-week subcutaneous toxicity study of prednisolone farnesylate (PNF) in rats]. Anabuki, K; Hoshiya, T; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H; Yamazaki, E, 1992)	0.28
" In the groups that received less than 1 mg/kg/day of PNF gel, there were no toxic signs induced by the drug."	( [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. Anabuki, K; Hoshiya, T; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H; Yamazaki, E, 1992)	0.28
"125 mg/kg/day group, there were no toxic signs induced by the drug."	( [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. Aikawa, T; Hatayama, K; Nishimura, S; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H, 1992)	0.28
" The results point to possible involvement of PKC in the toxic effect of farnesol which occurs with some degree of selectivity depending on cell origin."	( Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Melnykovych, G; Yazlovitskaya, EM, 1995)	0.29
" The essential oil had a significant toxic effect against early fourth stage larvae of Aedes aegypti L with an LC(50) value of 28."	( Immunotoxicity activity of the major essential oil of Filipendula glaberrima against Aedes aegypti L. Lee, SJ; Moon, HI, 2010)	0.36

Excerpt	Reference	Relevance
" The intracellular half-life of EFdA-triphosphate in PBMCs was determined to be >72 h following a single exposure to EFdA."	( Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Galkina, SA; Joshi, P; Kosikova, G; Moreno, ME; Murphey-Corb, M; Parniak, MA; Reeve, AB; Rivera, JM; Sarafianos, SG; Sloan, B; Stoddart, CA, 2015)	0.42

Excerpt	Reference	Relevance
" Herein, we investigated in human monocytes the effect of statins alone, and in combination with PPAR-gamma ligands on CD36 expression, as well as the molecular mechanisms underlying the regulatory action of statins."	( Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Domínguez, A; Ruiz-Velasco, N; Vega, MA, 2004)	0.32
" The abovementioned activity of VPA as a differentiation agent suggested that it might be worth investigating its possible therapeutic potential in synergistic combination with FTS."	( Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Biran, A; Brownstein, M; Haklai, R; Kloog, Y, 2011)	0.37
" Drug-drug interactions were assessed utilising the FICI, Bliss independence models and time-kill experiments."	( Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms. Bozó, A; Domán, M; Gesztelyi, R; Kardos, G; Kovács, R; Majoros, L; Nagy, F; Tóth, Z, 2016)	0.43
" Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent."	( The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. Bozó, A; Domán, M; Kardos, G; Kovács, R; Majoros, L; Varga, I, 2016)	0.43
" The aim of this work was to determine the effectiveness of externally added FAR in combination with fluconazole (FLC) on Candida albicans biofilm and on regulation of the ergosterol genes ERG20, ERG9, and ERG11."	( The impact of farnesol in combination with fluconazole on Candida albicans biofilm: regulation of ERG20, ERG9, and ERG11 genes. Bujdáková, H; Černáková, L; Dižová, S, 2018)	0.48
"We concluded that the responses of different fungal species against farnesol are variable, and different interactions may be observed when it is combined with different antifungals."	( In Vitro Effects of Farnesol Alone and in Combination with Antifungal Drugs Against Aspergillus Clinical Isolates. Onder, S; Oz, Y, 2021)	0.62

Excerpt	Reference	Relevance
" Thus, AKRs (1C15 in rats, and 1B10 and 1C3 in humans) may play an important role in controlling the bioavailability of FOH and GGOH."	( Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. El-Kabbani, O; Endo, S; Hara, A; Kanamori, A; Kitade, Y; Matsunaga, T; Ohno, S; Ohta, C; Soda, M; Tajima, K, 2011)	0.37
" This compromises its bioavailability if it were to be used along with vancomycin at the site of infection when the treatment needs to be administered in vivo."	( Sol-gel silica controlled release thin films for the inhibition of methicillin-resistant Staphylococcus aureus. Agrawal, A; Bhattacharyya, S; Ducheyne, P; Knabe, C, 2014)	0.4
" One of the ways to improve its therapeutic potential would be to enhance its bioavailability to cancer tissue by developing a method for targeted delivery."	( Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye. Chordia, MD; Chung, LW; Guan, Y; Li, J; Liu, ZQ; Pan, D; Wang, JP; Xiao, L; Yue, W; Zhang, Y, 2017)	0.46
" After a single oral administration in Balb/c mice, the relative bioavailability of FTS-IR783 was increased by 90."	( Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice. Deng, JH; Guan, Y; Huang, QJ; Huang, ZY; Liao, GC; Liu, ZQ; Lu, LL; Pan, DF; Qi, XX; Wang, Y; Yang, ML; Yao, JJ; Zhang, FX; Zhang, YM; Zhuang, XR, 2022)	0.72

Excerpt	Relevance	Reference
" At the end of the dosing period, increases in absolute and relative liver and kidney weights were seen in farnesol-treated rats."	( Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. Cwik, MJ; Horn, TL; Kapetanovic, IM; Long, L; McCormick, DL; Morrissey, RL, 2005)	0.33
" We examined the dose-response effects of FTS on the growth of MCF-7 breast cancer cells in vitro and in vivo."	( Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Lynch, AR; McPherson, RA; Neal, LR; Santen, RJ; Yue, W, 2006)	0.33
" Two-choice behavioral assays verified that the blend of (E,E)-farnesyl acetate and hexadecyl acetate (w/w: 2:1) attracted males at a dosage equivalent to the amounts of these compounds in one spider web, whereas neither compound alone aroused males."	( A two-component female-produced pheromone of the spider Pholcus beijingensis. Li, S; Xiao, Y; Zhang, J, 2009)	0.35
"Farnesol pretreatment decreased infarct size in a U-shaped dose-response manner where 1 mg/kg/day dose reached a statistically significant reduction (22."	( Cardioprotection by farnesol: role of the mevalonate pathway. Csonka, C; Csont, T; Ferdinandy, P; Görbe, A; Kocsis, GF; Murlasits, Z; Pálóczi, J; Szűcs, G; Török, S, 2013)	0.39
" EFdA was readily absorbed after oral dosing (5 mg/kg of body weight) in both mice and the rhesus macaque, with micromolar levels of the maximum concentration of drug in serum (Cmax) attained at 30 min and 90 min, respectively."	( Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Galkina, SA; Joshi, P; Kosikova, G; Moreno, ME; Murphey-Corb, M; Parniak, MA; Reeve, AB; Rivera, JM; Sarafianos, SG; Sloan, B; Stoddart, CA, 2015)	0.42
" Patients with stable disease or better repeated the dosing regimen."	( An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Fujisaka, Y; Furuse, J; Iwasa, T; Kitamura, H; Kurata, T; Nagashima, F; Nakagawa, K; Naruge, D; Okano, N; Shimizu, T, 2018)	0.48
" With increase in the dosage of farnesol, there was a noticeable decrease in the expression levels of PI3K, p-PI3K and p-Akt proteins."	( Antiproliferative activity of Farnesol in HeLa cervical cancer cells is mediated via apoptosis induction, loss of mitochondrial membrane potential (ΛΨm) and PI3K/Akt signalling pathway. Liu, HF; Shi, XJ; Wang, Y; Wang, YL, )	0.13

Product Category	Products
Beauty & Personal Care	3

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Dead Sea Naturals Skincare Starter Kit -- 1 Kit	Dead Sea Naturals	Beauty & Personal Care	caprylyl glycol, butylene glycol, aminomethyl propanol, methylpropanediol, citric acid, ascorbyl palmitate, alanine, allantoin, ascorbyl glucoside, ascorbic acid, bisabolol, cetearyl alcohol, cetyl alcohol, cetyl palmitate, chlorphenesin, citric acid, cocamidopropyl betaine, tocopherol, panthenol, pro vitamin B5, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycine, dimethicone, hexyl cinnamal, hydroxyethylcellulose, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, isopropyl myristate, kaolin, lactic acid, linalool, niacinamide, phenoxyethanol, peg-40 stearate, propylene glycol, salicylic acid, beta-sitosterol, sodium benzoate, sodium citrate, sodium hydroxide, sodium lactate, squalene, stearyl alcohol, trehalose, urea, zinc oxide	2024-11-29 10:47:42
NutriBiotic Face Creme -- 2 fl oz	NutriBiotic	Beauty & Personal Care	allantoin, vitamin C, benzyl alcohol, vitamin D3, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycerol monolaurate, phenoxyethanol, retinyl palmitate, squalene, stearic acid, stearyl alcohol, alpha lipoic acid, tocotrienol, tromethamine	2024-11-29 10:47:42
The Honey Pot Feminine Foaming Wash - Cucumber Aloe -- 5.51 fl oz	The Honey Pot	Beauty & Personal Care	amyl cinnamal, citric acid, benzyl benzoate, benzyl salicylate, citral, citric acid, cocamidopropyl betaine, tocopherol, ethylhexylglycerin, farnesol, tocopherol, geraniol, glycerin, hydroxycitronellal, lactic acid, limonene, linalool, phenoxyethanol, propylene glycol	2024-11-29 10:47:42

Role	Description
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
farnesol	A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
juvenile hormone III biosynthesis I	0	17
all-trans-farnesol biosynthesis	1	7
farnesylcysteine salvage pathway	2	15
Juvenile Hormone Synthesis	5	22
N-glycan biosynthesis	0	10
all-trans-farnesol biosynthesis	3	7
juvenile hormone III biosynthesis I	4	22
juvenile hormone III biosynthesis II	1	16

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	25.1189	5.6234	17.2929	31.6228	AID485281
15-lipoxygenase, partial	Homo sapiens (human)	Potency	15.8489	0.0126	10.6917	88.5700	AID887
USP1 protein, partial	Homo sapiens (human)	Potency	63.0957	0.0316	37.5844	354.8130	AID504865
TDP1 protein	Homo sapiens (human)	Potency	22.7265	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	45.9174	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	14.1254	0.1800	13.5574	39.8107	AID1460
AR protein	Homo sapiens (human)	Potency	48.9662	0.0002	21.2231	8,912.5098	AID743035; AID743063
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	60.3851	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	54.9410	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	66.6712	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	8.5982	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	63.4257	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	43.2771	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	32.7805	0.0002	29.3054	16,493.5996	AID743069; AID743075
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	43.6412	0.0010	24.5048	61.6448	AID743212
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	61.6448	0.0010	19.4141	70.9645	AID743191
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	44.6684	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	68.5896	0.0017	23.8393	78.1014	AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	53.9068	0.0578	21.1097	61.2679	AID1159526; AID1159528
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	61.1306	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	61.6448	0.0420	27.3789	61.6448	AID743210
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	36.4332	0.0006	27.2152	1,122.0200	AID720636; AID743219
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Cellular tumor antigen p53	Homo sapiens (human)	Potency	76.9588	0.0023	19.5956	74.0614	AID651631
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))	IC50 (µMol)	81.4000	0.0005	0.9767	10.0000	AID443292
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	Ki	430.0714	0.0008	1.0927	6.0000	AID1796581
Amine oxidase [flavin-containing] A	Homo sapiens (human)	Ki	430.0714	0.0019	2.3797	10.0000	AID1796581
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	IC50 (µMol)	43.5000	0.3000	3.2580	7.3000	AID1222388; AID1222389
Amine oxidase [flavin-containing] B	Homo sapiens (human)	Ki	430.0714	0.0006	1.7771	10.0000	AID1796581
Amine oxidase [flavin-containing] B	Bos taurus (cattle)	Ki	430.0714	0.0540	1.8390	6.0000	AID1796581
Amine oxidase [flavin-containing] B	Mus musculus (house mouse)	Ki	430.0714	0.1000	2.3790	6.0000	AID1796581
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
viral release from host cell	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
biogenic amine metabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
positive regulation of signal transduction	Amine oxidase [flavin-containing] A	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
acute-phase response	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to nutrient	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
animal organ regeneration	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to lipopolysaccharide	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to starvation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
biphenyl catabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to ethanol	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to glucocorticoid stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to estradiol stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to xenobiotic stimulus	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to toxic substance	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to aluminum ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to selenium ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
negative regulation of serotonin secretion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
phenylethylamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
substantia nigra development	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to lipopolysaccharide	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to ethanol	Amine oxidase [flavin-containing] B	Homo sapiens (human)
positive regulation of dopamine metabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to corticosterone	Amine oxidase [flavin-containing] B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
exo-alpha-sialidase activity	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
peptidase activator activity	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
electron transfer activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
identical protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membrane	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] A	Homo sapiens (human)
cytosol	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum chaperone complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cytochrome complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial envelope	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dendrite	Amine oxidase [flavin-containing] B	Homo sapiens (human)
neuronal cell body	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (859)

Assay ID	Title	Year	Journal	Article
AID407452	Decrease in HSP30 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406868	Decrease in CGD gene ortholog accession number orf19.3063 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407241	Increase in CGD gene ortholog accession number orf19.4980 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406323	Increase in CGD gene ortholog accession number orf19.4609 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407472	Decrease in CGD gene ortholog accession number orf19.6602 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767664	Antibacterial activity against Enterococcus durans BIO 0114 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406673	Decrease in GenBank accession number XP_459779.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405880	Increase in CGD gene ortholog accession number orf19.1421 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406697	Decrease in CGD gene ortholog accession number orf19.3815 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405857	Increase in CGD gene ortholog accession number orf19.4907 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407416	Increase in GenBank accession number NP_943640.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405895	Increase in CGD gene ortholog accession number orf19.2324 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407482	Decrease in HOF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374027	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 by micro-dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407109	Decrease in CGD gene ortholog accession number orf19.278 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405902	Increase in CGD gene ortholog accession number orf19.3015 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558446	Downregulation of S-adenosylmethionine synthase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407486	Decrease in CGD gene ortholog accession number orf19.6173 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406099	Increase in CGD gene ortholog accession number orf19.2538 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407305	Decrease in MSH6 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558670	Induction of ROS accumulation in mitochondria of Candida albicans SC5314 after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407442	Increase in CGD gene ortholog accession number orf19.5550 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558654	Induction of apoptosis in Candida albicans SC5314 assessed as mitochondrial degradation at 200 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406108	Increase in CGD gene ortholog accession number orf19.1195 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767725	Antimicrobial activity against Streptococcus pyogenes ATCC 19615 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767675	Antibacterial activity against Serratia marcescens ATCC 13880 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767692	Bactericidal activity against Enterococcus faecalis ATCC 51299 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406282	Increase in CGD gene ortholog accession number orf19.2982 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405666	Increase in CGD gene ortholog accession number orf19.2335 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407259	Increase in NAD3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407227	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 6 hrs of bacterial growth measured after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374057	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 at 1000 ug/ml (Rvb = oxacillin alone MIC = >256 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407419	Increase in PUT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405651	Increase in CGD gene ortholog accession number orf19.2310 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558658	Induction of apoptosis in Candida albicans SC5314 at 40 uM after 24 hrs by TUNEL assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405695	Increase in ENA2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407451	Decrease in MAF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405875	Increase in POT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767691	Bactericidal activity against Staphylococcus epidermidis 70 D assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406276	Increase in ACC1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1070521	Antimicrobial activity against Mycobacterium tuberculosis H37Rv by BACTEC radiometric assay	2014	Journal of natural products, Mar-28, Volume: 77, Issue:3	Airborne antituberculosis activity of Eucalyptus citriodora essential oil.
AID1374032	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 relative to untreated oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407466	Decrease in ERG1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407446	Decrease in CGD gene ortholog accession number orf19.433 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374075	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 at 1000 ug/ml by checkerboard assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID573463	Drug release from hydroxyapatite bound tooth-binding micelles formed from biocompatible pluronic copolymers modified with alendronat assessed as compound release into medium after 48 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Tooth-binding micelles for dental caries prevention.
AID405671	Increase in CGD gene ortholog accession number orf19.7261 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406691	Decrease in CGD gene ortholog accession number orf19.4903 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767673	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558452	Upregulation of 6-Phosphogluconate dehydrogenase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1767704	Ratio of MBC to MIC against Streptococcus agalactiae ATCC 13813	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767716	Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406664	Decrease in CGD gene ortholog accession number orf19.3084 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407422	Increase in CGD gene ortholog accession number orf19.2608 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405661	Increase in LAG41 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID343716	Superoxide-scavenging activity assessed as inhibition of formation of WST1 formazan	2008	Journal of natural products, Jul, Volume: 71, Issue:7	C-geranylated chalcones from the stems of Angelica keiskei with superoxide-scavenging activity.
AID1767681	Antibacterial activity against Escherichia coli EOL 931 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406304	Increase in ARG2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767667	Antibacterial activity against Streptococcus mutans ATCC 25175 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1102000	Antifeedant activity against adult of Leptinotarsa decemlineata in Capsicum annuum by choice test	2002	Journal of agricultural and food chemistry, Nov-20, Volume: 50, Issue:24	Antifeedant effects of marine halogenated monoterpenes.
AID496221	Antifungal activity against Candida albicans in YPD medium at => 300 uM after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID407220	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558428	Antiproliferative activity against Candida albicans SC5314 assessed as cell killing at 10 uM after 24 hrs by MTS assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406702	Decrease in CGD gene ortholog accession number orf19.1158 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496240	Antifungal activity against log phase culture of Candida albicans at 10 to 300 uM treated directly to growing cultures measured after 4 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406880	Decrease in FMP27 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406113	Increase in CGD gene ortholog accession number orf19.3185 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767658	Antibacterial activity against Staphylococcus aureus MED 55 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407222	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 2 hrs of bacterial growth measured after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405686	Increase in CGD gene ortholog accession number orf19.6373 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374033	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 relative to untreated ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID406299	Increase in CGD gene ortholog accession number orf19.4044 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407111	Decrease in GenBank accession number XP_457517.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406870	Decrease in TRL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406472	Increase in CGD gene ortholog accession number orf19.6973 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407233	Reduction in ERG9 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407248	Increase in GenBank accession number NP_983467.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407475	Decrease in CGD gene ortholog accession number orf19.4789 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407392	Increase in GenBank accession number NP_943649.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558435	Downregulation of G-beta-like protein expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1374041	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS123 at 1000 ug/ml (Rvb = ampicillin alone MIC = 12 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID573460	Antibacterial activity against Streptococcus mutans UA159 assessed as log decrease in bacterial count per biofilm recovered from hydroxyapatite disc using low dose compound containing hydroxyapatite bound tooth-binding micelles formed from biocompatible p	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Tooth-binding micelles for dental caries prevention.
AID407450	Decrease in STE23 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405897	Increase in CGD gene ortholog accession number orf19.5963 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558448	Upregulation of Coproporphyrinogen III oxidase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407311	Decrease in CGD gene ortholog accession number orf19.3446 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405878	Increase in CGD gene ortholog accession number orf19.2749 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405669	Increase in CGD gene ortholog accession number orf19.7097 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406308	Increase in CGD gene ortholog accession number orf19.7235 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407469	Decrease in CGD gene ortholog accession number orf19.5212 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407226	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 6 hrs of bacterial growth measured after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407412	Increase in CGD gene ortholog accession number orf19.5015 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407256	Increase in GAR1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767686	Antibacterial activity against Escherichia coli EPEC E234969 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558666	Increase in MCA1 expression in Candida albicans SC5314 at 10 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406481	Increase in CGD gene ortholog accession number orf19.4133 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406287	Increase in GDB1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID332912	Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method	1994	Journal of natural products, Jan, Volume: 57, Issue:1	Naturally occurring antiacne agents.
AID406689	Decrease in CGD gene ortholog accession number orf19.1850 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407082	Decrease in CGD gene ortholog accession number orf19.4637 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407410	Increase in CGD gene ortholog accession number orf19.5015 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406285	Increase in CGD gene ortholog accession number orf19.6442 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406102	Increase in CGD gene ortholog accession number orf19.6233 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407440	Increase in SNZ1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406095	Increase in CGD gene ortholog accession number orf19.6019 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406704	Decrease in CGD gene ortholog accession number orf19.6100 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406910	Decrease in CGD gene ortholog accession number orf19.5586 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407414	Increase in HTS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406495	Increase in CGD gene ortholog accession number orf19.323 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406688	Decrease in CGD gene ortholog accession number orf19.7149 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767715	Antimicrobial activity against Streptococcus pyogenes ATCC 19615 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406293	Increase in KEX2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407255	Increase in GLN1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407399	Increase in CGD gene ortholog accession number orf19.7238 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406503	Decrease in CGD gene ortholog accession number orf19.5683 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405681	Increase in CGD gene ortholog accession number orf19.2998 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374042	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS123 at 1000 ug/ml relative to ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1374029	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 by micro-dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1374037	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 at 1000 ug/ml (Rvb = ampicillin alone MIC = 16 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1767660	Antibacterial activity against Staphylococcus epidermidis 70 D assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405645	Increase in BMS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406487	Increase in WRS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406318	Increase in CGD gene ortholog accession number orf19.1457 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406092	Increase in ERB1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767677	Antibacterial activity against Shigella flexneri CCCD S006 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767738	Antibiofilm activity against drug-resistant Streptococcus sobrinus ATCC 27351 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407216	Antifungal activity against Candida parapsilosis CLIB214 assessed as induction of cell death at 50 uM added 4 hrs after bacterial growth after 2 hrs by colony counting method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406288	Increase in CGD gene ortholog accession number orf19.1933 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407218	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition in presence of 10% fetal calf serum at 30 degC	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1163511	Cytotoxicity against human PANC1 cells under nutrient-rich condition after 24 hrs by WST8 dye based assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents.
AID407298	Decrease in CGD gene ortholog accession number orf19.136 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407401	Increase in GenBank accession number AAF06350.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767719	Antimicrobial activity against Staphylococcus aureus MED 55 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405861	Increase in GIR2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406509	Decrease in CGD gene ortholog accession number orf19.2097 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405649	Increase in UBI4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496237	Antifungal activity against stationary phase culture of Candida albicans in YPD medium at 10 to 300 uM at 30 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406895	Decrease in CGD gene ortholog accession number orf19.2308 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407221	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406670	Decrease in CGD gene ortholog accession number orf19.5253 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407413	Increase in CGD gene ortholog accession number orf19.2288 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407393	Increase in ILV5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767706	Ratio of MBC to MIC against Streptococcus mutans ATCC 25175	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407398	Increase in SNQ2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406674	Decrease in CGD gene ortholog accession number orf19.1219 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406067	Increase in CGD gene ortholog accession number orf19.3481 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406699	Decrease in CGD gene ortholog accession number orf19.6254 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407406	Increase in CGD gene ortholog accession number orf19.497 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407417	Increase in NDE1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407077	Decrease in GAL10 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407117	Decrease in MNL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407103	Decrease in CGD gene ortholog accession number orf19.1595 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407430	Increase in CGD gene ortholog accession number orf19.2735 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407086	Decrease in CGD gene ortholog accession number orf19.3434 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407239	Antifungal activity against Candida albicans assessed as microbila killing effect	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407265	Decrease in CGD gene ortholog accession number orf19.6283 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406325	Increase in CGD gene ortholog accession number orf19.4931 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407079	Decrease in CGD gene ortholog accession number orf19.1362 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407091	Decrease in PTR2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407435	Increase in CGD gene ortholog accession number orf19.1552 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407242	Increase in GenBank accession number NP_943638.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406916	Decrease in CGD gene ortholog accession number orf19.6984 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406671	Decrease in CGD gene ortholog accession number orf19.1728 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406303	Increase in CRZ2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID573462	Antibacterial activity against Streptococcus mutans UA159 assessed as log decrease in bacterial count per biofilm recovered from hydroxyapatite disc using high dose compound containing hydroxyapatite bound tooth-binding micelles formed from biocompatible	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Tooth-binding micelles for dental caries prevention.
AID1767720	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406684	Decrease in CGD gene ortholog accession number orf19.1608 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407480	Decrease in CGD gene ortholog accession number orf19.1496 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406291	Increase in SNF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406889	Decrease in CGD gene ortholog accession number orf19.2892 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406516	Decrease in CGD gene ortholog accession number orf19.6323 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406512	Decrease in SOL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407268	Decrease in CGD gene ortholog accession number orf19.2756 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407093	Decrease in CGD gene ortholog accession number orf19.6476 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID667072	Antifungal activity against Candida albicans DAY185 assessed as lowest compound concentration causing =>80% reduction in cell viability after 48 hrs by XTT assay	2012	Journal of natural products, Apr-27, Volume: 75, Issue:4	Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.
AID407266	Decrease in CGD gene ortholog accession number orf19.5274 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407263	Increase in STI1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405891	Increase in ERG7 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374076	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 at 1000 ug/ml by checkerboard assay	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407296	Decrease in CGD gene ortholog accession number orf19.6444 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406079	Increase in CGD gene ortholog accession number orf19.6082 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407261	Increase in NADH51 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID47225	In vitro inhibition of yeast-to-hypha transition in candida albicans	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID406484	Increase in CGD gene ortholog accession number orf19.4544 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558434	Upregulation of POR1 expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1767737	Antibiofilm activity against drug-resistant Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558657	Induction of apoptosis in Candida albicans SC5314 assessed as activation of caspase activity at 200 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407479	Decrease in HOS2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406909	Decrease in CGD gene ortholog accession number orf19.7511 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407208	Antifungal activity against Candida parapsilosis CLIB214 assessed as reduction of biofilm formation at 100 uM added 4 hrs after bacterial growth by crystal violet assay	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767727	Antimicrobial activity against Streptococcus sobrinus ATCC 27351 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767663	Antibacterial activity against Enterococcus faecalis ATCC 51299 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406298	Increase in HOG1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407432	Increase in CGD gene ortholog accession number orf19.444 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558449	Upregulation of Branched chain amino acid transaminase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407438	Increase in CGD gene ortholog accession number orf19.2115 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767683	Antibacterial activity against Escherichia coli EHEC 933 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407294	Decrease in CGD gene ortholog accession number orf19.1177 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406508	Decrease in MES1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407215	Cell cycle arrest in Candida parapsilosis CLIB214 assessed as accumulation at G2/M phase at 50 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406278	Increase in CGD gene ortholog accession number orf19.1368 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407071	Decrease in CGD gene ortholog accession number orf19.6637 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374060	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 at 1000 ug/ml relative to oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID406894	Decrease in CGD gene ortholog accession number orf19.3655 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405650	Increase in ERG6 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406093	Increase in GenBank accession number NP_943647.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558454	Upregulation of Heat shock protein 70 expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406877	Decrease in CGD gene ortholog accession number orf19.4372 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406301	Increase in CGD gene ortholog accession number orf19.3023 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407307	Decrease in CGD gene ortholog accession number orf19.7604 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767731	Antibiofilm activity against drug-resistant Staphylococcus aureus MED 55 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407283	Decrease in CGD gene ortholog accession number orf19.479 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405667	Increase in CGD gene ortholog accession number orf19.1814 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405678	Increase in CGD gene ortholog accession number orf19.1642 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406874	Decrease in CGD gene ortholog accession number orf19.538 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767679	Antibacterial activity against Escherichia coli ATCC 35218 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407284	Decrease in CGD gene ortholog accession number orf19.4595 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406893	Decrease in CGD gene ortholog accession number orf19.3235 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405689	Increase in CGD gene ortholog accession number orf19.7234 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558430	Downregulation of Putative stress response protein expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406494	Increase in DOT5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406900	Decrease in GenBank accession number XP_457879.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405872	Increase in ISW2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406286	Increase in CGD gene ortholog accession number orf19.1675 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407468	Decrease in CYB2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406892	Decrease in CGD gene ortholog accession number orf19.5769 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496226	Antifungal activity against exponential phase culture of Candida albicans in GPP medium at 40 uM after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID407231	Increase in ADH7 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406087	Increase in STP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558466	Upregulation of Putative aspartate aminotransferase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407083	Decrease in ZCF30 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406313	Increase in CGD gene ortholog accession number orf19.3617 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406479	Increase in CGD gene ortholog accession number orf19.1092 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558460	Upregulation of Putative mitochondrial aconitate dehydrogenase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406708	Decrease in CGD gene ortholog accession number orf19.6462 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767697	Bactericidal activity against Streptococcus sobrinus ATCC 27351 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405682	Increase in CGD gene ortholog accession number orf19.3291 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407087	Decrease in PDC2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407274	Decrease in CGD gene ortholog accession number orf19.2770 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407098	Decrease in CGD gene ortholog accession number orf19.1723 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405874	Increase in GDH3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406104	Increase in CGD gene ortholog accession number orf19.5897 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767690	Bactericidal activity against Staphylococcus epidermidis ATCC 12228 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407483	Decrease in CGD gene ortholog accession number orf19.2366 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407075	Decrease in CGD gene ortholog accession number orf19.2666 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407289	Decrease in CGD gene ortholog accession number orf19.4231 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558437	Downregulation of Glyceraldehyde-3-phosphate dehydrogenase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407107	Decrease in CGD gene ortholog accession number orf19.5022 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406686	Decrease in CGD gene ortholog accession number orf19.5780 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406667	Decrease in ERG9 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406679	Decrease in CGD gene ortholog accession number orf19.804 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407207	Increase in CGD gene ortholog accession number orf19.2070 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406296	Increase in CGD gene ortholog accession number orf19.5247 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406903	Decrease in CGD gene ortholog accession number orf19.6713 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767712	Antimicrobial activity against Enterococcus faecalis ATCC 51299 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Teicoplanin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405692	Increase in CGD gene ortholog accession number orf19.3349 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407487	Decrease in CGD gene ortholog accession number orf19.2659 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406097	Increase in CGD gene ortholog accession number orf19.1019 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407403	Increase in HOM6 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407099	Decrease in CGD gene ortholog accession number orf19.2788 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406327	Increase in CGD gene ortholog accession number orf19.7290 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406085	Increase in CGD gene ortholog accession number orf19.7048 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405867	Increase in CGD gene ortholog accession number orf19.4739 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496224	Antifungal activity against log phase culture of Candida albicans in GPP medium at 100 uM after 1 hr by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID405658	Increase in HTA3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406319	Increase in CGD gene ortholog accession number orf19.2484 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406290	Increase in CGD gene ortholog accession number orf19.4633 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558651	Induction of ROS accumulation in mitochondria of Candida albicans SC5314 at 200 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558433	Downregulation of Phosphoglycerate mutase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406676	Decrease in CGD gene ortholog accession number orf19.1028 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406522	Decrease in CTN1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406907	Decrease in CGD gene ortholog accession number orf19.296 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405859	Increase in CGD gene ortholog accession number orf19.1335 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407100	Decrease in CGD gene ortholog accession number orf19.4700 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407219	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition in presence of 10% fetal calf serum at 37 degC	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407293	Decrease in ZCF23 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405684	Increase in CGD gene ortholog accession number orf19.949 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374034	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 relative to untreated oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID558667	Induction of apoptosis in Candida albicans SC5314 assessed as cell death level at 40 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407101	Decrease in CGD gene ortholog accession number orf19.6488 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558432	Downregulation of Riboflavin synthase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558660	Induction of apoptosis in Candida albicans SC5314 at 200 uM after 24 hrs by TUNEL assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406488	Increase in UGT51C1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407444	Decrease in CAT8 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405683	Increase in GenBank accession number NP_943643.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407212	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added 4 hrs after bacterial growth within 2 hrs by cell counting method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407425	Increase in CGD gene ortholog accession number orf19.6730 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406879	Decrease in CGD gene ortholog accession number orf19.3051 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406709	Decrease in RIA1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558663	Down regulation of in MCA1 expression in Candida albicans SC5314 at 40 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406913	Decrease in PFK1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407244	Increase in GenBank accession number NP_943636.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496230	Antifungal activity against exponential phase culture of Candida albicans in YPD medium at 10 to 300 uM at 25 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406283	Increase in CGD gene ortholog accession number orf19.192 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407252	Increase in GenBank accession number NP_943634.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407247	Increase in GCV1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406073	Increase in CGD gene ortholog accession number orf19.5407 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558458	Upregulation of Heat shock protein 90 expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1767672	Antibacterial activity against Klebsiella pneumoniae ATCC 1705 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558647	Upregulation of Phosphoglycerate mutase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406326	Increase in CGD gene ortholog accession number orf19.2167 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405896	Increase in CGD gene ortholog accession number orf19.6062 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405883	Increase in CGD gene ortholog accession number orf19.7196 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406310	Increase in CGD gene ortholog accession number orf19.1026 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1849967	Substrate activity at 6xHis-tagged Streptococcus mutans UdpK expressed in Escherichia coli BL-21(DE3) assessed as measuring ADP level in presence of ATP/NADH by PK/LDH coupled assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Undecaprenol kinase: Function, mechanism and substrate specificity of a potential antibiotic target.
AID407072	Decrease in INT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406511	Decrease in CGD gene ortholog accession number orf19.6046 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID336125	Antimycobacterial activity against Mycobacterium tuberculosis by radiorespirometric bioassay	2002	Journal of natural products, Sep, Volume: 65, Issue:9	African elephant sesquiterpenes. II. Identification and synthesis of new derivatives of 2,3-dihydrofarnesol.
AID406109	Increase in CHO2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407474	Decrease in CGD gene ortholog accession number orf19.7065 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496223	Antifungal activity against log phase culture of Candida albicans in GPP medium at 40 uM after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406081	Increase in FMP45 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID667073	Antifungal activity against Candida albicans DAY185 assessed as inhibition of biofilm formation after 48 hrs by XTT assay	2012	Journal of natural products, Apr-27, Volume: 75, Issue:4	Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.
AID1767702	Ratio of MBC to MIC against Enterococcus faecalis ATCC 51299	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405652	Increase in CGD gene ortholog accession number orf19.5627 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407113	Decrease in CGD gene ortholog accession number orf19.4898 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405693	Increase in CGD gene ortholog accession number orf19.3647 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407105	Decrease in CGD gene ortholog accession number orf19.194 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406324	Reduction in GCN3 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406474	Increase in CGD gene ortholog accession number orf19.1230 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558665	Increase in MCA1 expression in Candida albicans SC5314 at 5 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406498	Decrease in CGD gene ortholog accession number orf19.1482 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406480	Increase in CGD gene ortholog accession number orf19.5364 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767739	Antimicrobial activity against Staphylococcus aureus MED 55 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405893	Increase in CGD gene ortholog accession number orf19.1954 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405866	Increase in GRE3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406902	Decrease in CGD gene ortholog accession number orf19.6281 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406692	Decrease in CGD gene ortholog accession number orf19.6797 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406866	Decrease in PIN4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405865	Increase in CGD gene ortholog accession number orf19.843 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767693	Bactericidal activity against Enterococcus durans BIO 0114 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID496222	Antifungal activity against stationary phase culture of Candida albicans in GPP medium up to 300 uM after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406698	Decrease in TEM1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407089	Decrease in CGD gene ortholog accession number orf19.3806 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407471	Decrease in CGD gene ortholog accession number orf19.6816 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407428	Increase in HSP78 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407463	Decrease in CGD gene ortholog accession number orf19.5515 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406070	Increase in CGD gene ortholog accession number orf19.5598 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406490	Increase in CGD gene ortholog accession number orf19.308 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558653	Induction of apoptosis in Candida albicans SC5314 assessed as mitochondrial degradation at 100 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1767717	Antimicrobial activity against Streptococcus sobrinus ATCC 27351 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407315	Decrease in CGD gene ortholog accession number orf19.7629 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405903	Increase in ARP3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767661	Antibacterial activity against Enterococcus faecalis ATCC 6569 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767705	Ratio of MBC to MIC against Streptococcus pyogenes ATCC 19615	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767723	Antimicrobial activity against Enterococcus durans BIO 0114 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Teicoplanin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406322	Increase in CGD gene ortholog accession number orf19.5416 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407210	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406665	Decrease in CGD gene ortholog accession number orf19.1881 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407286	Decrease in CGD gene ortholog accession number orf19.21 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405889	Increase in RPN2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406114	Increase in CGD gene ortholog accession number orf19.7256 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558444	Downregulation of Dihydroxy acid dehydratase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405663	Increase in CGD gene ortholog accession number orf19.4243 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406284	Increase in VPS4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558662	Increase in MCA1 expression in Candida albicans SC5314 at 100 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1374030	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by micro-dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID405679	Increase in DBP8 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407313	Decrease in CGD gene ortholog accession number orf19.5388 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767709	Antimicrobial activity against Staphylococcus aureus MED 55 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405892	Increase in CGD gene ortholog accession number orf19.3456 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558659	Induction of apoptosis in Candida albicans SC5314 at 100 uM after 24 hrs by TUNEL assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID320483	Toxicity against ip dosed mouse after 14 days	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	Influence of heterocyclic and oxime-containing farnesol analogs on quorum sensing and pathogenicity in Candida albicans.
AID405884	Increase in CGD gene ortholog accession number orf19.4488 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405670	Increase in ADO1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407485	Decrease in PCK1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558442	Downregulation of carboxymethylenebutenolidase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407457	Decrease in CGD gene ortholog accession number orf19.3332 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405673	Increase in CGD gene ortholog accession number orf19.6810 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767700	Ratio of MBC to MIC against Staphylococcus epidermidis ATCC 12228	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406878	Decrease in CGD gene ortholog accession number orf19.7325 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405869	Increase in CGD gene ortholog accession number orf19.4757 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407394	Increase in MCR1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407308	Decrease in OPT5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374062	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS123 at 1000 ug/ml relative to oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID558451	Upregulation of Catalase A expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407299	Decrease in CGD gene ortholog accession number orf19.7010 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407458	Decrease in CGD gene ortholog accession number orf19.4157 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558456	Upregulation of Heat shock protein 90 homologue expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406882	Decrease in KIS2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407206	Increase in GRP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406690	Decrease in CGD gene ortholog accession number orf19.1850 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406094	Increase in CGD gene ortholog accession number orf19.6369 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406281	Increase in CGD gene ortholog accession number orf19.2346 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374036	Potentiation of ampicillin-induced antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 at 1000 ug/ml relative to ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID406080	Increase in SMF12 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558461	Upregulation of Heat shock protein 60 expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID1767668	Antibacterial activity against Streptococcus sobrinus ATCC 27351 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405646	Increase in CSP37 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767713	Antimicrobial activity against Enterococcus durans BIO 0114 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Teicoplanin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407461	Decrease in CGD gene ortholog accession number orf19.409 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406096	Increase in SCH9 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407291	Decrease in CGD gene ortholog accession number orf19.4911 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405657	Increase in TIF4631 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406518	Decrease in HEM2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405655	Increase in CGD gene ortholog accession number orf19.5544 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767659	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407456	Decrease in CGD gene ortholog accession number orf19.5129 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407237	Effect on GAD1 gene expression in Candida parapsilosis CLIB214 by microarray based transcriptional profiling	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767732	Antibiofilm activity against drug-resistant Staphylococcus epidermidis 70 D assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406703	Decrease in STE3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407477	Decrease in CGD gene ortholog accession number orf19.6360 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406524	Decrease in AMO2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406309	Increase in CHT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558462	Upregulation of Aldose reductase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406294	Increase in CGD gene ortholog accession number orf19.3100 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406279	Increase in CGD gene ortholog accession number orf19.25 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406912	Decrease in CGD gene ortholog accession number orf19.2565 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407235	Effect on membrane lipid localization in ERG9 gene expression in Candida parapsilosis CLIB214 assessed as uniform staining at 50 uM after 1 hr by filipin staining	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407411	Increase in RPN1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558655	Induction of apoptosis in Candida albicans SC5314 assessed as activation of caspase activity at 40 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406098	Increase in CGD gene ortholog accession number orf19.5612 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407240	Increase in CGD gene ortholog accession number orf19.5517 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407405	Increase in SPT6 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405870	Increase in CGD gene ortholog accession number orf19.779 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496236	Antifungal activity against stationary phase culture of Candida albicans in YPD medium at 10 to 300 uM at 25 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID558668	Induction of apoptosis in Candida albicans SC5314 assessed as cell death level at 100 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406101	Increase in RPS6A gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407279	Decrease in FBP1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407402	Increase in CGD gene ortholog accession number orf19.2564 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406876	Decrease in RIM21 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767666	Antibacterial activity against Streptococcus pyogenes ATCC 19615 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406112	Increase in PUT2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406520	Decrease in CGD gene ortholog accession number orf19.2737 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406675	Decrease in RLM1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406513	Decrease in CGD gene ortholog accession number orf19.273 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405879	Increase in CGD gene ortholog accession number orf19.5617 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767671	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405888	Increase in CGD gene ortholog accession number orf19.854 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407084	Decrease in CGD gene ortholog accession number orf19.4210 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407431	Increase in GenBank accession number NP_943635.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405863	Increase in CGD gene ortholog accession number orf19.5710 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406519	Decrease in CGD gene ortholog accession number orf19.337 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406683	Decrease in RPN3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405899	Increase in NOC2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767694	Bactericidal activity against Streptococcus agalactiae ATCC 13813 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407460	Decrease in CGD gene ortholog accession number orf19.1976 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407112	Decrease in CGD gene ortholog accession number orf19.7387 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496220	Antifungal activity against Candida albicans in YPD medium up to 300 uM after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406896	Decrease in CGD gene ortholog accession number orf19.587 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406873	Decrease in CGD gene ortholog accession number orf19.1500 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406086	Increase in CGD gene ortholog accession number orf19.7568 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407278	Decrease in CGD gene ortholog accession number orf19.4203 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407427	Increase in CYS4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406901	Decrease in GenBank accession number XP_460297.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406677	Decrease in CGD gene ortholog accession number orf19.2541 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407068	Decrease in CGD gene ortholog accession number orf19.7521 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407407	Increase in KRE30 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406905	Decrease in CGD gene ortholog accession number orf19.4985 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407280	Decrease in CGD gene ortholog accession number orf19.1007 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406906	Decrease in CGD gene ortholog accession number orf19.5040 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406477	Reduction in CHS5 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767670	Antibacterial activity against Stenotrophomonas maltophilia EM 0104assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405881	Increase in CGD gene ortholog accession number orf19.1429 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405688	Increase in CGD gene ortholog accession number orf19.1372 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496229	Antifungal activity against exponential phase culture of Candida albicans in GPP medium at 10 to 300 uM at 37 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID1767688	Bactericidal activity against Staphylococcus aureus ATCC 43300 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406891	Decrease in CGD gene ortholog accession number orf19.5751 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406492	Increase in CGD gene ortholog accession number orf19.1392 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406706	Decrease in CCC1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767734	Antibiofilm activity against drug-resistant Enterococcus durans BIO01 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405664	Increase in CGD gene ortholog accession number orf19.7243 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406117	Increase in CGD gene ortholog accession number orf19.7020 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407081	Decrease in CGD gene ortholog accession number orf19.1634 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407455	Decrease in CGD gene ortholog accession number orf19.6071 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407473	Decrease in CGD gene ortholog accession number orf19.6044 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407478	Decrease in CGD gene ortholog accession number orf19.6294 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407400	Increase in BGL2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767696	Bactericidal activity against Streptococcus mutans ATCC 25175 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767728	Antimicrobial activity against Staphylococcus aureus ATCC 27351 assessed assessed as reduction in bacterial growth at 1/2 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406908	Decrease in CGD gene ortholog accession number orf19.7631 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558464	Upregulation of Manganese superoxide dismutase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405900	Increase in RTA3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407115	Decrease in CGD gene ortholog accession number orf19.4763 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374059	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 at 1000 ug/ml (Rvb = oxacillin alone MIC = 32 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID406517	Decrease in KEL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767730	Antibiofilm activity against drug-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406103	Increase in TEF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767729	Antimicrobial activity against Staphylococcus aureus MED 55 assessed assessed as reduction in bacterial growth at 1/2 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407426	Increase in CGD gene ortholog accession number orf19.1317 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407395	Increase in GenBank accession number XP_460627.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496227	Antifungal activity against exponential phase culture of Candida albicans in GPP medium at 10 to 300 uM at 25 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID1767703	Ratio of MBC to MIC against Enterococcus durans BIO 0114	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407209	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 10 to 20 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406483	Increase in CGD gene ortholog accession number orf19.6080 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406507	Decrease in CGD gene ortholog accession number orf19.6186 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407312	Decrease in CGD gene ortholog accession number orf19.3356 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407453	Decrease in CGD gene ortholog accession number orf19.6134 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407443	Decrease in CGD gene ortholog accession number orf19.1943 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407467	Decrease in CGD gene ortholog accession number orf19.6687 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767674	Antibacterial activity against Proteus mirabilis ATCC 25933 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767718	Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407277	Decrease in SAP5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405665	Increase in CGD gene ortholog accession number orf19.3544 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407301	Decrease in CGD gene ortholog accession number orf19.2136 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407282	Decrease in CGD gene ortholog accession number orf19.3451 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406915	Decrease in PCL7 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407429	Increase in CGD gene ortholog accession number orf19.7297 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407300	Decrease in DPP1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374039	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 at 1000 ug/ml (Rvb = ampicillin alone MIC = 16 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1767722	Antimicrobial activity against Enterococcus faecalis ATCC 51299 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Teicoplanin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406320	Increase in ERG4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID407420	Increase in ATP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558431	Downregulation of Translational elongation factor 1 expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558453	Upregulation of Pyruvate decarboxylase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID320482	Effect on quorum sensing in Candida albicans assessed as inhibition of germ tube formation	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	Influence of heterocyclic and oxime-containing farnesol analogs on quorum sensing and pathogenicity in Candida albicans.
AID558467	Upregulation of Glutathione reductase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405674	Increase in CGD gene ortholog accession number orf19.658 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374038	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 at 1000 ug/ml relative to ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1767669	Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405659	Increase in ALR1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407264	Decrease in LEU42 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406669	Decrease in CGD gene ortholog accession number orf19.4449 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406082	Increase in CGD gene ortholog accession number orf19.6417 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407262	Increase in CDC60B gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558459	Upregulation of Putative Rho protein GDP dissociation factor expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405868	Increase in GCD1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406523	Decrease in GAL7 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767656	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406681	Decrease in CGD gene ortholog accession number orf19.833 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767685	Antibacterial activity against Escherichia coli EIEC E20851 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767682	Antibacterial activity against Escherichia coli ETEC 2589093 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405694	Increase in CGD gene ortholog accession number orf19.1953 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407090	Decrease in CGD gene ortholog accession number orf19.1476 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558447	Upregulation of Putative mitochondrial aconitate hydratase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406685	Decrease in CGD gene ortholog accession number orf19.606 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407424	Increase in CGD gene ortholog accession number orf19.5533 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1101999	Antifeedant activity against adult of Myzus persicae (green peach aphid) in Hordeum vulgare by choice test	2002	Journal of agricultural and food chemistry, Nov-20, Volume: 50, Issue:24	Antifeedant effects of marine halogenated monoterpenes.
AID1374035	Potentiation of ampicillin-induced antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 at 1000 ug/ml (Rvb = ampicillin alone MIC = 0.5 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407073	Decrease in DPB2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405676	Increase in ARD gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407281	Decrease in CGD gene ortholog accession number orf19.1905 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406300	Increase in CGD gene ortholog accession number orf19.6371 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558652	Induction of apoptosis in Candida albicans SC5314 assessed as mitochondrial degradation at 40 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407246	Increase in GenBank accession number NP_943637.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405654	Increase in CGD gene ortholog accession number orf19.1536 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407225	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 4 hrs of bacterial growth measured after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406316	Increase in CGD gene ortholog accession number orf19.4681 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407267	Decrease in CGD gene ortholog accession number orf19.530 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407288	Decrease in CGD gene ortholog accession number orf19.2194 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767710	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405855	Increase in SPL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558648	Upregulation of NADH-cytochrome b5 reductase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406886	Decrease in PHO91 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407273	Decrease in CGD gene ortholog accession number orf19.3603 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496233	Antifungal activity against stationary phase culture of Candida albicans in GPP medium at 10 to 300 uM at 25 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID407245	Increase in CGD gene ortholog accession number orf19.171 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558445	Downregulation of Pyruvate kinase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407449	Decrease in CGD gene ortholog accession number orf19.4760 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407236	Effect on GDH2 gene expression in Candida parapsilosis CLIB214 by microarray based transcriptional profiling	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407104	Decrease in YHB1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407396	Increase in CGD gene ortholog accession number orf19.2917 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406663	Decrease in QCR2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405852	Increase in CGD gene ortholog accession number orf19.6578 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406917	Decrease in GSG1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406693	Decrease in CGD gene ortholog accession number orf19.1852 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558457	Upregulation of Aryl-alcohol dehydrogenase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407249	Increase in DBP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767687	Antimicrobial activity against Staphylococcus aureus ATCC 27351 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407437	Increase in PXP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406871	Decrease in CGD gene ortholog accession number orf19.1647 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405882	Increase in PDB1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405668	Increase in NIT2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405894	Increase in CGD gene ortholog accession number orf19.1222 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406314	Increase in CGD gene ortholog accession number orf19.5399 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406881	Decrease in DAG7 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406311	Increase in CGD gene ortholog accession number orf19.188 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767707	Ratio of MBC to MIC against Streptococcus sobrinus ATCC 27351	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558438	Downregulation of Enolase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407436	Increase in GenBank accession number NP_943645.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406489	Increase in CGD gene ortholog accession number orf19.631 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1222388	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID406496	Increase in CGD gene ortholog accession number orf19.6539 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407108	Decrease in CGD gene ortholog accession number orf19.728 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406105	Increase in NCP1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407433	Increase in GenBank accession number NP_943641.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406678	Decrease in CGD gene ortholog accession number orf19.6171 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID47395	In vitro inhibition of yeast cell growth of candida albicans at a concentration of 100 ug/mL	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID558441	Downregulation of Heat shock protein 60 expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405687	Increase in CGD gene ortholog accession number orf19.72 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406116	Increase in DAL9 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405653	Increase in CGD gene ortholog accession number orf19.1541 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406485	Increase in CGD gene ortholog accession number orf19.2208 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558465	Upregulation of Mitochondrial 2-enoyl thioester reductase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406883	Decrease in POL30 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407470	Decrease in SNQ2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407076	Decrease in CGD gene ortholog accession number orf19.4851 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405853	Increase in CGD gene ortholog accession number orf19.2439 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406897	Decrease in ZCF12 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407390	Increase in ASC1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374056	Potentiation of oxacillin-induced antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 at 1000 ug/ml relative to oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407306	Decrease in CGD gene ortholog accession number orf19.5156 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496225	Antifungal activity against log phase culture of Candida albicans in GPP medium at 300 uM after 4 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406090	Increase in MRP20 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767733	Antibiofilm activity against drug-resistant Enterococcus faecalis ATCC 51299 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405675	Increase in ALD5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID573459	Antibacterial activity against Streptococcus mutans UA159	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Tooth-binding micelles for dental caries prevention.
AID406682	Decrease in GCV2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407232	Reduction in ERG1 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406672	Decrease in SGS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406680	Decrease in CGD gene ortholog accession number orf19.6804 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407234	Effect on membrane lipid localization in ERG9 gene expression in Candida parapsilosis CLIB214 assessed as growing bud tip staining at 50 uM after 1 hr by filipin staining	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407465	Decrease in ERG251 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558664	Increase in MCA1 expression in Candida albicans SC5314 at 2.5 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405876	Increase in CGD gene ortholog accession number orf19.1890 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406661	Decrease in CGD gene ortholog accession number orf19.5735 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558436	Downregulation of GRE3 expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407295	Decrease in CGD gene ortholog accession number orf19.1676 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406089	Increase in DIP2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405877	Increase in CGD gene ortholog accession number orf19.5661 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406888	Decrease in CGD gene ortholog accession number orf19.6976 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406914	Decrease in CGD gene ortholog accession number orf19.4953 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1101998	Antifeedant activity against adult of Rhopalosiphum padi in Hordeum vulgare by choice test	2002	Journal of agricultural and food chemistry, Nov-20, Volume: 50, Issue:24	Antifeedant effects of marine halogenated monoterpenes.
AID407434	Increase in CGD gene ortholog accession number orf19.6018 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558439	Downregulation of ATP synthase subunit D expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407484	Decrease in CGD gene ortholog accession number orf19.5877 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496231	Antifungal activity against exponential phase culture of Candida albicans in YPD medium at 10 to 300 uM at 30 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406514	Decrease in CGD gene ortholog accession number orf19.3649 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406885	Decrease in SDS22 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496234	Antifungal activity against stationary phase culture of Candida albicans in GPP medium at 10 to 300 uM at 30 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID407445	Decrease in CGD gene ortholog accession number orf19.731 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407067	Decrease in CGD gene ortholog accession number orf19.3231 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407275	Decrease in CGD gene ortholog accession number orf19.5919 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496239	Antifungal activity against exponential phase culture of Candida albicans at 10 to 300 uM treated directly to growing cultures measured after 4 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406660	Decrease in ARG11 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406478	Reduction in VTC3 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407408	Increase in GLT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405864	Increase in CGD gene ortholog accession number orf19.37 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496238	Antifungal activity against stationary phase culture of Candida albicans in YPD medium at 10 to 300 uM at 37 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID407228	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 8 hrs of bacterial growth measured after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407243	Increase in TUF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767684	Antibacterial activity against Escherichia coli EAEC I 4913 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406898	Decrease in ADP1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407409	Increase in YCP4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407476	Decrease in CGD gene ortholog accession number orf19.1070 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406694	Decrease in CGD gene ortholog accession number orf19.4253 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406074	Increase in CGD gene ortholog accession number orf19.6407 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407448	Decrease in PDX3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407070	Decrease in CGD gene ortholog accession number orf19.672 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405886	Increase in CAG1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374040	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 at 1000 ug/ml relative to ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407238	Increase in GLN1 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406306	Increase in CGD gene ortholog accession number orf19.6843 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558656	Induction of apoptosis in Candida albicans SC5314 assessed as activation of caspase activity at 100 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407078	Decrease in CGD gene ortholog accession number orf19.413 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405858	Increase in CGD gene ortholog accession number orf19.6766 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558669	Induction of apoptosis in Candida albicans SC5314 assessed as cell death level at 200 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID496235	Antifungal activity against stationary phase culture of Candida albicans in GPP medium at 10 to 300 uM at 37 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406701	Decrease in CGD gene ortholog accession number orf19.5406 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496232	Antifungal activity against exponential phase culture of Candida albicans in YPD medium at 10 to 300 uM at 37 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID1767665	Antibacterial activity against Streptococcus agalactiae ATCC 13813 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1374031	Potentiation of ampicillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 relative to untreated ampicillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID1767714	Antimicrobial activity against Streptococcus agalactiae ATCC 13813 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406500	Decrease in ARF3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406486	Increase in CDC20 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767695	Bactericidal activity against Streptococcus pyogenes ATCC 19615 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407309	Decrease in CGD gene ortholog accession number orf19.2455 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407211	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 100 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767736	Antibiofilm activity against drug-resistant Streptococcus pyogenes ATCC 19615 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1767708	Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407251	Increase in HSP90 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID320484	Effect on rate of cell growth in Candida albicans at > 100 uM	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	Influence of heterocyclic and oxime-containing farnesol analogs on quorum sensing and pathogenicity in Candida albicans.
AID406904	Decrease in CGD gene ortholog accession number orf19.1531 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406075	Increase in CGD gene ortholog accession number orf19.5378 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407439	Increase in CGD gene ortholog accession number orf19.1754 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407085	Decrease in CGD gene ortholog accession number orf19.5074 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406315	Increase in CGD gene ortholog accession number orf19.4801 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407260	Increase in CGD gene ortholog accession number orf19.5356 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1101029	Antifeedant activity against Myzus persicae (green peach aphid) assessed feeding settling inhibition index at 50 ug/cm2 relative to untreated control	2000	Journal of agricultural and food chemistry, Aug, Volume: 48, Issue:8	Structure- and species-dependent insecticidal effects of neo-clerodane diterpenes.
AID407257	Increase in CGD gene ortholog accession number orf19.4371 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406872	Decrease in CGD gene ortholog accession number orf19.5755 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405862	Increase in CGD gene ortholog accession number orf19.5602 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407447	Decrease in CGD gene ortholog accession number orf19.2940 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407095	Decrease in CGD gene ortholog accession number orf19.2101 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406321	Increase in CGD gene ortholog accession number orf19.1682 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407088	Decrease in CGD gene ortholog accession number orf19.540 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767735	Antibiofilm activity against drug-resistant Streptococcus agalactiae ATCC 13813 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based microtiter plate method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID558468	Upregulation of Acetyl-CoA hydrolase/transferase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407287	Decrease in CGD gene ortholog accession number orf19.2342 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406887	Decrease in CGD gene ortholog accession number orf19.894 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558429	Antiproliferative activity against Candida albicans SC5314 assessed as cell killing after 24 hrs by MTS assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407303	Decrease in DUR4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407297	Decrease in HGT5 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406515	Decrease in CGD gene ortholog accession number orf19.3060 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406707	Decrease in PIKA gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405873	Increase in CGD gene ortholog accession number orf19.345 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406077	Increase in CGD gene ortholog accession number orf19.4900 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406292	Increase in CGD gene ortholog accession number orf19.5333 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405898	Increase in ACH1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406473	Reduction in NPL4 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407080	Decrease in CGD gene ortholog accession number orf19.292 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406662	Decrease in CGD gene ortholog accession number orf19.7118 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406710	Decrease in AMS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407314	Decrease in GenBank accession number XP_451524. 1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405662	Increase in PRT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406506	Decrease in CGD gene ortholog accession number orf19.3573 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407069	Decrease in PGA55 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406696	Decrease in CGD gene ortholog accession number orf19.4960 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406666	Decrease in CGD gene ortholog accession number orf19.4947 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406115	Increase in CGD gene ortholog accession number orf19.6393 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406078	Increase in LSP1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767689	Bactericidal activity against Staphylococcus aureus MED 55 assessed as bacterial killing incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407092	Decrease in CGD gene ortholog accession number orf19.2697 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406106	Increase in ALS2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767726	Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Ampicillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407290	Decrease in CGD gene ortholog accession number orf19.3704 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407481	Decrease in CGD gene ortholog accession number orf19.6621 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406277	Increase in CGD gene ortholog accession number orf19.5771 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407110	Decrease in CGD gene ortholog accession number orf19.3951 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407106	Decrease in CGD gene ortholog accession number orf19.1050 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406475	Increase in CGD gene ortholog accession number orf19.2527 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406521	Decrease in PGA12 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID358269	Cicatrizant activity in mouse assessed as wound healing by tensile strength method	2001	Journal of natural products, Oct, Volume: 64, Issue:10	(+)-epi-Alpha-bisabolol [correction of bisbolol] is the wound-healing principle of Peperomia galioides: investigation of the in vivo wound-healing activity of related terpenoids.
AID407102	Decrease in CGD gene ortholog accession number orf19.4376 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407270	Decrease in SCT2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1163512	Stimulation of cell growth in human PANC1 cells at 6.25 to 50 uM under nutrient-deprived condition after 24 hrs by WST8 dye based assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents.
AID406499	Decrease in CGD gene ortholog accession number orf19.2328 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405856	Increase in CDC12 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374061	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS123 at 1000 ug/ml (Rvb = oxacillin alone MIC = 24 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID407250	Increase in GenBank accession number NP_943644.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407217	Antifungal activity against Candida parapsilosis CLIB214 assessed as induction of cell death at 50 uM added 4 hrs after bacterial growth after 2 hrs by propidium iodide staining method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406687	Decrease in ARR3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406911	Decrease in CGD gene ortholog accession number orf19.5952 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405860	Increase in CGD gene ortholog accession number orf19.5318 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406068	Increase in CGD gene ortholog accession number orf19.2715 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407230	Increase in GRP2 gene expression in Candida parapsilosis CLIB214 by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406289	Increase in CGD gene ortholog accession number orf19.4750 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406312	Increase in CGD gene ortholog accession number orf19.3799 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767678	Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406482	Increase in CGD gene ortholog accession number orf19.7032 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407464	Decrease in CGD gene ortholog accession number orf19.5307 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405871	Increase in VCX1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407254	Increase in RPS7A gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407310	Decrease in CGD gene ortholog accession number orf19.2149 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407094	Decrease in CGD gene ortholog accession number orf19.355 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558450	Upregulation of Alcohol dehydrogenase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID405691	Increase in CGD gene ortholog accession number orf19.6524 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406695	Decrease in SFC1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405660	Increase in CGD gene ortholog accession number orf19.5847 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767698	Ratio of MBC to MIC against Staphylococcus aureus ATCC 43300	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406890	Decrease in CGD gene ortholog accession number orf19.6211 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407441	Increase in CGD gene ortholog accession number orf19.7378 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406501	Decrease in CGD gene ortholog accession number orf19.5920 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558463	Upregulation of Coproporphyrinogen III oxidase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407097	Decrease in CGD gene ortholog accession number orf19.101 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407391	Increase in GenBank accession number NP_943639.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767699	Ratio of MBC to MIC against Staphylococcus aureus MED 55	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406899	Decrease in CGD gene ortholog accession number orf19.2400 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405656	Increase in MVD gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406668	Decrease in CGD gene ortholog accession number orf19.673 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406107	Increase in CGD gene ortholog accession number orf19.966 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406884	Decrease in CGD gene ortholog accession number orf19.2517 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407116	Decrease in MED8 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406867	Decrease in CGD gene ortholog accession number orf19.804 (SGD ortholog YPR011C) expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406869	Decrease in CGD gene ortholog accession number orf19.6744 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406083	Increase in CGD gene ortholog accession number orf19.1747 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405901	Increase in PDE2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407074	Decrease in CGD gene ortholog accession number orf19.7589 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405685	Increase in CGD gene ortholog accession number orf19.239 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767724	Antimicrobial activity against Streptococcus agalactiae ATCC 13813 assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of Oxacillin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406497	Decrease in CBF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407229	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 8 hrs of bacterial growth measured after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406491	Increase in CGD gene ortholog accession number orf19.3509 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406505	Decrease in CGD gene ortholog accession number orf19.1355 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405648	Increase in CAT1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558661	Increase in MCA1 expression in Candida albicans SC5314 at 40 uM after 4 hrs by quantitative PCR analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558649	Induction of ROS accumulation in mitochondria of Candida albicans SC5314 at 40 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407454	Decrease in PTC4 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1222389	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID406076	Increase in CGD gene ortholog accession number orf19.4621 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407271	Decrease in CGD gene ortholog accession number orf19.2049 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406875	Decrease in CGD gene ortholog accession number orf19.5180 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407302	Decrease in AOX1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407421	Increase in CGD gene ortholog accession number orf19.822 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406072	Increase in ICL1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374055	Potentiation of oxacillin-induced antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 at 1000 ug/ml (Rvb = oxacillin alone MIC = 0.4 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID405690	Increase in CGD gene ortholog accession number orf19.6902 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407272	Decrease in CTN1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374058	Potentiation of oxacillin-induced antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS100 at 1000 ug/ml relative to oxacillin alone	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID573461	Antibacterial activity against Streptococcus mutans UA159 assessed as log decrease in bacterial count per biofilm recovered from hydroxyapatite disc using medium dose compound containing hydroxyapatite bound tooth-binding micelles formed from biocompatibl	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Tooth-binding micelles for dental caries prevention.
AID406100	Increase in CGD gene ortholog accession number orf19.182 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767676	Antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium ATCC 14028 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406476	Increase in CGD gene ortholog accession number orf19.1230 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405677	Increase in CGD gene ortholog accession number orf19.4963 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406295	Increase in CGD gene ortholog accession number orf19.7237 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406502	Decrease in CGD gene ortholog accession number orf19.2761 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405887	Increase in CGD gene ortholog accession number orf19.5910 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407459	Decrease in CGD gene ortholog accession number orf19.100 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406510	Decrease in RIB1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407423	Increase in CGD gene ortholog accession number orf19.7353 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406084	Increase in CGD gene ortholog accession number orf19.6555 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406110	Increase in MNN2 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407397	Increase in RPS22A gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID558650	Induction of ROS accumulation in mitochondria of Candida albicans SC5314 at 100 uM after 3 hrs by Fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558443	Downregulation of Glyceraldehyde-3-phosphate dehydrogenase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID558440	Downregulation of NADH:quinone oxidoreductase expression in Candida albicans SC5314 at 200 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID407462	Decrease in DES1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407285	Decrease in CGD gene ortholog accession number orf19.6805 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406700	Decrease in CGD gene ortholog accession number orf19.719 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407269	Decrease in RIM13 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407304	Decrease in CGD gene ortholog accession number orf19.6650 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407114	Decrease in CGD gene ortholog accession number orf19.1307 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1768534	Binding affinity to Mycobacterium tuberculosis CYP124A1 by UV-visible spectrophotometric analysis	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Synthesis and interaction of terminal unsaturated chemical probes with Mycobacterium tuberculosis CYP124A1.
AID443292	Inhibition of Influenza Virus A/PR/8/34 neuraminidase chemiluminescence-based enzyme inhibition assay	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.
AID1767701	Ratio of MBC to MIC against Staphylococcus epidermidis 70 D	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406297	Increase in CGD gene ortholog accession number orf19.2575 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407223	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 2 hrs of bacterial growth measured after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407292	Decrease in UME6 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405885	Increase in HAS1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407213	Cell cycle arrest in Candida parapsilosis CLIB214 assessed as accumulation at G1 phase at 50 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406504	Decrease in CGD gene ortholog accession number orf19.2724 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1374028	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS123 by micro-dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Potentiation of the activity of β-lactam antibiotics by farnesol and its derivatives.
AID406111	Increase in CGD gene ortholog accession number orf19.6117 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407224	Antifungal activity against Candida parapsilosis CLIB214 assessed as growth inhibition at 50 uM added after 4 hrs of bacterial growth measured after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767721	Antimicrobial activity against Staphylococcus epidermidis 70 D assessed assessed as reduction in bacterial growth at 1/8 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID407253	Increase in GenBank accession number NP_943632.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407418	Increase in ELF1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406071	Increase in PLB3 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1070523	Partition coefficient, log K of the compound in n-hexane/methyl tert-butylether/acetonitrile 10:1:10 solvent system by HSCCC/EECCC analysis	2014	Journal of natural products, Mar-28, Volume: 77, Issue:3	Airborne antituberculosis activity of Eucalyptus citriodora essential oil.
AID406302	Increase in CGD gene ortholog accession number orf19.2465 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407258	Increase in GenBank accession number NP_943633.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406280	Increase in CGD gene ortholog accession number orf19.2446 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767662	Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406317	Increase in CGD gene ortholog accession number orf19.7069 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405672	Increase in BRE1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767680	Antibacterial activity against Escherichia coli STEC 2C1 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID405854	Increase in CGD gene ortholog accession number orf19.1755 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407276	Decrease in FRE7 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407415	Increase in GenBank accession number NP_943636.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405890	Increase in CGD gene ortholog accession number orf19.1864 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407096	Decrease in CGD gene ortholog accession number orf19.3835 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767711	Antimicrobial activity against Staphylococcus epidermidis 70 D assessed assessed as reduction in bacterial growth at 1/4 times of drug MIC in the presence of vancomycin by microdilution method	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406705	Decrease in CGD gene ortholog accession number orf19.3458 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406305	Increase in CGD gene ortholog accession number orf19.7421 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1767657	Antibacterial activity against Staphylococcus aureus ATCC 43300 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID406091	Increase in CGD gene ortholog accession number orf19.2367 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406088	Increase in CGD gene ortholog accession number orf19.3501 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405647	Increase in GenBank accession number NP_943642.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406118	Increase in CGD gene ortholog accession number orf19.813 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1289353	Selectivity ratio of IC50 for human recombinant KDM1A to human recombinant MAO-B	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Recent Progress in Histone Demethylase Inhibitors.
AID558455	Upregulation of Alanine/arginine aminopeptidase expression in Candida albicans SC5314 at 40 uM after 24 hrs by MALDI-TOF MS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Farnesol-induced apoptosis in Candida albicans.
AID406069	Increase in CGD gene ortholog accession number orf19.7270 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406493	Increase in CGD gene ortholog accession number orf19.457 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407404	Increase in GenBank accession number NP_943631.1 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID405680	Increase in CDC42 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID406307	Increase in REG1 gene expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID407214	Cell cycle arrest in Candida parapsilosis CLIB214 assessed as accumulation at S phase at 50 uM added 4 hrs after bacterial growth	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID496228	Antifungal activity against exponential phase culture of Candida albicans in GPP medium at 10 to 300 uM at 30 degC after 24 hrs by methylene blue assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
AID406659	Decrease in CGD gene ortholog accession number orf19.478 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transcriptional response of Candida parapsilosis following exposure to farnesol.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1796581	MAO Inhibition Assay from Article 10.1074/jbc.M500949200: \\Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.\\	2005	The Journal of biological chemistry, Apr-22, Volume: 280, Issue:16	Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	204 (18.25)	18.7374
1990's	183 (16.37)	18.2507
2000's	290 (25.94)	29.6817
2010's	336 (30.05)	24.3611
2020's	105 (9.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (0.78%)	5.53%
Reviews	68 (5.86%)	6.00%
Case Studies	3 (0.26%)	4.05%
Observational	0 (0.00%)	0.25%
Other	1,081 (93.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
alpha-hydroxyglutarate 2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.. 2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.	2.01	1	0	2-hydroxydicarboxylic acid; dicarboxylic fatty acid	metabolite; mouse metabolite
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.6	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
4-hydroxyphenylacetic acid 4-hydroxyphenylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.	2.07	1	0	monocarboxylic acid; phenols	fungal metabolite; human metabolite; mouse metabolite; plant metabolite
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	1.99	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	2.41	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
adenine [no description available]	2.9	4	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
benzyl alcohol Benzyl Alcohol: A colorless liquid with a sharp burning taste and slight odor. It is used as a local anesthetic and to reduce pain associated with LIDOCAINE injection. Also, it is used in the manufacture of other benzyl compounds, as a pharmaceutic aid, and in perfumery and flavoring.. hydroxytoluene : Any member of the class of toluenes carrying one or more hydroxy substituents.. benzyl alcohol : An aromatic alcohol that consists of benzene bearing a single hydroxymethyl substituent.. aromatic alcohol : Any alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.. aromatic primary alcohol : Any primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.	2.53	2	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	1.94	1	0	halide anion; monoatomic bromine
1-butanol 1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.	1.95	1	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	2.01	1	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
carbamates [no description available]	2.05	1	0	amino-acid anion
choline [no description available]	2.9	4	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.25	1	0	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.36	2	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
hydrochloric acid Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.	1.94	1	0	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.74	3	0	coumarins	fluorescent dye; human metabolite; plant metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	1.98	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
phloroglucinol Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.	2.05	1	0	benzenetriol; phenolic donor	algal metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2	1	0	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.52	2	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
3,3-dimethylallyl pyrophosphate 3,3-dimethylallyl pyrophosphate: isomeric with isopentenyl pyrophosphate. prenyl diphosphate : A prenol phosphate that is a phosphoantigen comprising the O-pyrophosphate of prenol.	2.72	3	0	prenol phosphate	epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
1,4-dihydroxy-2-naphthoic acid [no description available]	2.4	2	0	dihydroxy monocarboxylic acid; naphthalenediols; naphthohydroquinone; naphthoic acid	Escherichia coli metabolite
hexachlorocyclohexane Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.	2.01	1	0	chlorocyclohexane
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.65	3	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	1.94	1	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
hydroxylamine amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.	1.98	1	0	hydroxylamines	algal metabolite; bacterial xenobiotic metabolite; EC 1.1.3.13 (alcohol oxidase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; nitric oxide donor; nucleophilic reagent
indole [no description available]	1.98	1	0	indole; polycyclic heteroarene	Escherichia coli metabolite
lipoamide Lipozyme: lipase from Rhizomucor miehei immobilized on anion exchange resin	2.06	1	0	dithiolanes; monocarboxylic acid amide	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	1.95	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	1.94	1	0	cyclitol; hexol
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
1-octanol 1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). octan-1-ol : An octanol carrying the hydroxy group at position 1.	2.42	2	0	octanol; primary alcohol	antifungal agent; bacterial metabolite; fuel additive; kairomone; plant metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	4.01	4	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.41	2	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
diphosphoric acid diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.	2.65	3	0	acyclic phosphorus acid anhydride; phosphorus oxoacid	Escherichia coli metabolite
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	2.02	1	0	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
1-propanol 1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.	1.97	1	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
propionic acid propionic acid : A short-chain saturated fatty acid comprising ethane attached to the carbon of a carboxy group.	2.01	1	0	saturated fatty acid; short-chain fatty acid	antifungal drug
isopentenyl pyrophosphate isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells. isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent.	3.23	6	0	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
menthol Menthol: A monoterpene cyclohexanol produced from mint oils.	2.72	3	0	p-menthane monoterpenoid; secondary alcohol	volatile oil component
perillic acid perillic acid: d-limonene metabolite; structure given in first source	2	1	0	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid	antineoplastic agent; human metabolite; mouse metabolite
1,2-dimethylhydrazine 1,2-Dimethylhydrazine: A DNA alkylating agent that has been shown to be a potent carcinogen and is widely used to induce colon tumors in experimental animals.. 1,2-dimethylhydrazine : A member of the class of hydrazines that is hydrazine in which one of the hydrogens attached to each nitrogen is replaced by a methyl group. A powerful DNA alkylating agent and carcinogen, it is used to induce colon cancer in laboratory rats and mice.	7.06	1	0	hydrazines	alkylating agent; carcinogenic agent
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.01	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.45	2	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
mercaptoethanol Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	1.95	1	0	alkanethiol; primary alcohol	geroprotector
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.02	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
4-aminopyridine [no description available]	2.01	1	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
phenytoin [no description available]	2.01	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	7.6	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	3.11	5	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
theophylline [no description available]	1.95	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
benzethonium Benzethonium: Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.	2.73	3	0	alkylbenzene
benzo(a)pyrene Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.	2.46	2	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	2.42	2	0
caffeine [no description available]	1.98	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.05	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
carvedilol [no description available]	2.06	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.05	1	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	2.53	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetyl alcohol cetyl alcohol: has been used for eczema, skin irritations; RN given refers to parent cpd; structure. hexadecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of sixteen carbon atoms.. hexadecan-1-ol : A long-chain primary fatty alcohol that is hexadecane substituted by a hydroxy group at position 1.	3.54	2	0	hexadecanol; long-chain primary fatty alcohol	algal metabolite; flavouring agent; human metabolite; plant metabolite
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.41	2	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.1	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.38	2	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.03	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
eucalyptol [no description available]	2.48	2	0
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	7.59	2	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2	1	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	2.01	1	0	diarylmethane
dibutyl phthalate Dibutyl Phthalate: A plasticizer used in most plastics and found in water, air, soil, plants and animals. It may have some adverse effects with long-term exposure.. dibutyl phthalate : A phthalate ester that is the diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol. Although used extensively as a plasticiser, it is a ubiquitous environmental contaminant that poses a risk to humans.	7.05	1	0	diester; phthalate ester	EC 3.2.1.20 (alpha-glucosidase) inhibitor; environmental contaminant; metabolite; plasticiser; teratogenic agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.03	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dihydrocytochalasin b dihydrocytochalasin B: inhibits cell motility in many eucaryotic cells	2.01	1	0
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.06	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
ether Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.	2.01	1	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	2.01	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2	1	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	4.05	13	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	2.03	1	0
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	1.94	1	0
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	2	1	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.38	2	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
beta-thujaplicin beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.	1.98	1	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.43	2	0	phenanthridines	fluorochrome; intercalator
hydroxyurea [no description available]	2.31	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
indolepropanol phosphate indolepropanol phosphate: binds specifically to the alpha subunit, but not to the beta subunit of tryptophan synthase. 3-(indol-3-yl)propyl phosphate : An monoalkyl phosphate compound having an O-3-(indol-3-yl)propyl substituent.	1.99	1	0	indoles; monoalkyl phosphate
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.44	2	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.25	1	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.47	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
lauric acid dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.	2.41	2	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite
letrozole [no description available]	2.01	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.03	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.02	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.02	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	8.89	3	0	dichlorobenzene; ether; imidazoles
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.63	3	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
niflumic acid Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.	2.06	1	0	aromatic carboxylic acid; pyridines
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.06	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.41	2	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
propoxur Propoxur: A carbamate insecticide.. propoxur : A carbamate ester that is phenyl methylcarbamate substituted at position 2 by a propan-2-yloxy group.	2.6	1	0	aromatic ether; carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.06	1	0	benzothiazoles
safrole Safrole: A member of the BENZODIOXOLES that is a constituent of several VOLATILE OILS, notably SASSAFRAS oil. It is a precursor in the synthesis of the insecticide PIPERONYL BUTOXIDE and the drug N-methyl-3,4-methylenedioxyamphetamine (MDMA).. safrole : A member of the class of benzodioxoles that is 1,3-benzodioxole which is substituted by an allyl group at position 5. It is found in several plants, including black pepper, cinnamon and nutmeg, and is present in several essential oils, notably that of sassafras. It has insecticidal properties and has been used as a topical antiseptic. Although not thought to pose a significant carcinogenic risk to humans, findings of weak carcinogenicity in rats have resulted in the banning of its (previously widespread) use in perfumes and soaps, and as a food additive.	1.98	1	0	benzodioxoles	flavouring agent; insecticide; metabolite; plant metabolite
sc-10 N-(m-heptyl)-5-chloro-1-naphthalenesulfonamide: protein kinase C activator	2.01	1	0	naphthalenes; sulfonic acid derivative
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.01	1	0	pyridines
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	2.01	1	0	quaternary ammonium ion
2-thiosalicylic acid 2-thiosalicylic acid: a degradation product of thimerosal; RN given refers to parent cpd. thiosalicylic acid : A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid.	2.01	1	0	sulfanylbenzoic acid	antipyretic; non-narcotic analgesic
triclosan [no description available]	2.04	1	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.03	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
zinc chloride zinc chloride: RN given refers to parent cpd. zinc dichloride : A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions.	1.98	1	0	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	3.92	13	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.38	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
thymidine [no description available]	2.68	3	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.02	1	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	2.06	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	2.01	1	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
aldosterone [no description available]	1.99	1	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2.05	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	2.36	2	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	7.41	1	0	pilocarpine	antiglaucoma drug
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	2.79	3	0	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
biguanides Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.	2.04	1	0	guanidines
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	2.89	4	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.01	1	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.41	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.01	1	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.01	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
allyl isothiocyanate allyl isothiocyanate: used in the manufacture of flavors, war gases; medical use as a counterirritant; structure. allyl isothiocyanate : An isothiocyanate with the formula CH2=CHCH2N=C=S. A colorless oil with boiling point 152degreeC, it is responsible for the pungent taste of mustard, horseradish, and wasabi.	2.45	2	0	alkenyl isothiocyanate; isothiocyanate	antimicrobial agent; antineoplastic agent; apoptosis inducer; lachrymator; metabolite
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.39	2	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.06	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2.05	1	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	1.95	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
uridine [no description available]	1.95	1	0	uridines	drug metabolite; fundamental metabolite; human metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	1.99	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
galactose galactopyranose : The pyranose form of galactose.	1.94	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.73	3	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	1.99	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.68	3	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	6.66	20	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.69	3	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	1.95	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methylene blue Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.	2.41	1	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.09	5	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ethyl methanesulfonate Ethyl Methanesulfonate: An antineoplastic agent with alkylating properties. It also acts as a mutagen by damaging DNA and is used experimentally for that effect.. ethyl methanesulfonate : A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with ethanol.	2.03	1	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; genotoxin; mutagen; teratogenic agent
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	1.96	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	1.94	1	0	lactose
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	3.47	8	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.01	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cytidine triphosphate Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.	1.98	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	2.63	2	0	penicillin	antibacterial agent; antibacterial drug
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.68	3	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
dimethylformamide Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.	1.95	1	0	formamides; volatile organic compound	geroprotector; hepatotoxic agent; polar aprotic solvent
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	2.07	1	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.63	2	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
n-pentanol n-pentanol: RN given refers to parent cpd. pentan-1-ol : A short-chain primary fatty alcohol that is pentane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It has been isolated from Melicope ptelefolia.	3.81	3	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
medroxyprogesterone acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.44	2	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.	2.02	1	0	aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
ethylene oxide Ethylene Oxide: A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794). oxirane : A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.	2.06	1	0	gas molecular entity; oxacycle; saturated organic heteromonocyclic parent	allergen; mouse metabolite; mutagen
linalool linalool: RN given refers to parent cpd without isomeric designation; structure. linalool : A monoterpenoid that is octa-1,6-diene substituted by methyl groups at positions 3 and 7 and a hydroxy group at position 3. It has been isolated from plants like Ocimum canum.	3.31	6	0	monoterpenoid; tertiary alcohol	antimicrobial agent; fragrance; plant metabolite; volatile oil component
isoprene isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.	2	1	0	alkadiene; hemiterpene; volatile organic compound	plant metabolite
acrylamide [no description available]	7.11	1	0	acrylamides; N-acylammonia; primary carboxamide	alkylating agent; carcinogenic agent; Maillard reaction product; mutagen; neurotoxin
alpha-pinene [no description available]	1.98	1	0	pinene	plant metabolite
2,6-dihydroxyanthraquinone 2,6-dihydroxyanthraquinone: structure given in first source. anthraflavic acid : A dihydroxyanthraquinone that is anthracene substituted by hydroxy groups at C-3 and C-7 and oxo groups at C-9 and C-10.	2.06	1	0	dihydroxyanthraquinone	antimutagen; plant metabolite
pyocyanine Pyocyanine: Antibiotic pigment produced by Pseudomonas aeruginosa.. pyocyanine : An iminium betaine that is 5-methylphenazin-5-ium which is substituted at position 1 by an oxidanidyl group. An antibiotic pigment produced by Pseudomonas aeruginosa.	2.78	3	0	iminium betaine; phenazines	antibacterial agent; bacterial metabolite; biological pigment; virulence factor
xylitol xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.	4.33	4	1
thymol Thymol: A phenol obtained from thyme oil or other volatile oils used as a stabilizer in pharmaceutical preparations, and as an antiseptic (antibacterial or antifungal) agent.. thymol : A phenol that is a natural monoterpene derivative of cymene.	2.71	3	0	monoterpenoid; phenols	volatile oil component
1-naphthol 1-naphthol: RN given refers to parent cpd. 1-naphthol : A naphthol carrying a hydroxy group at position 1.. hydroxynaphthalene : Any member of the class of naphthalenes that is naphthalene carrying one or more hydroxy groups.	2.06	1	0	naphthol	genotoxin; human xenobiotic metabolite
isatin tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;	2.02	1	0	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.48	2	0	xanthene
methyleugenol methyleugenol: structure	3.04	4	0	phenylpropanoid
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	2.96	4	0	butan-4-olide	metabolite; neurotoxin
carvone carvone: an oxidized derivative of limonene; RN given refers to cpd without isomeric designation; L-carvone has spearmint flavor, D-carvone has dill/caraway flavor. carvone : A p-menthane monoterpenoid that consists of cyclohex-2-enone having methyl and isopropenyl substituents at positions 2 and 5, respectively.	2.46	2	0	botanical anti-fungal agent; carvones	allergen
gamma-terpinene gamma-terpinene: RN given refers to gamma-terpinene; structure. gamma-terpinene : One of three isomeric monoterpenes differing in the positions of their two double bonds (alpha- and beta-terpinene being the others). In gamma-terpinene the double bonds are at the 1- and 4-positions of the p-menthane skeleton.	2.11	1	0	cyclohexadiene; monoterpene	antioxidant; human xenobiotic metabolite; plant metabolite; volatile oil component
citronellal citronellal: aldehyde of citronellol; found in citronella oil. citronellal : A monoterpenoid, the main component of citronella oil which gives it its distinctive lemon aroma.	2.11	1	0	aldehyde; monoterpenoid	antifungal agent; metabolite
acrolein [no description available]	3.18	5	0	enal	herbicide; human xenobiotic metabolite; toxin
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	1.97	1	0	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
hydroxycitronellal hydroxycitronellal : The tertiary alcohol arising from addition of water across the C=C double bond of citronellal.	2.21	1	0	tertiary alcohol	allergen; fragrance
succinic anhydride [no description available]	2	1	0	cyclic dicarboxylic anhydride; tetrahydrofurandione
maleic anhydride Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns.. maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid.	2	1	0	cyclic dicarboxylic anhydride; furans	allergen
cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.	2.06	1	0	cyclohexanols; secondary alcohol	solvent
pentane Pentanes: Five-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. pentane : A straight chain alkane consisting of 5 carbon atoms.	2	1	0	alkane; volatile organic compound	non-polar solvent; refrigerant
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.94	4	0	pyrrole; secondary amine
tetrahydrofuran oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.	2.01	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.01	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
1-hexanol 1-hexanol: RN given refers to parent cpd. hexanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of six carbon atoms.. hexan-1-ol : A primary alcohol that is hexane substituted by a hydroxy group at position 1.	2.94	4	0	hexanol; primary alcohol	alarm pheromone; antibacterial agent; fragrance; plant metabolite
heptanol Heptanol: A colorless liquid with a fragrant odor. It is used as an intermediate, solvent and in cosmetics.. heptanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of seven carbon atoms.. heptan-1-ol : A primary alcohol that is heptane substituted by a hydroxy group at position 1. It has been isolated from Capillipedium parviflorum.	1.98	1	0	heptanol; primary alcohol	flavouring agent; fragrance; gap junctional intercellular communication inhibitor; plant metabolite
n-decyl alcohol n-decyl alcohol: RN given refers to parent cpd. decanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of ten carbon atoms.. decan-1-ol : A fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of ten carbon atoms.	1.98	1	0	decanol; primary alcohol	metabolite; pheromone; protic solvent
n-dodecane dodecane : A straight-chain alkane with 12 carbon atoms. It has been isolated from the essential oils of various plants including Zingiber officinale (ginger).	2	1	0	alkane	plant metabolite
undecan-1-ol undecan-1-ol : A primary alcohol that is undecane substituted by a hydroxy group at position 1.. undecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of eleven carbon atoms.	3.54	2	0	primary alcohol; undecanol	flavouring agent; plant metabolite
dodecanol Dodecanol: A saturated 12-carbon fatty alcohol obtained from coconut oil fatty acids. It has a floral odor and is used in detergents, lubricating oils, and pharmaceuticals. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). dodecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of twelve carbon atoms.. dodecan-1-ol : A primary alcohol that is dodecane in which a hydrogen from one of the methyl groups is replaced by a hydroxy group. It is registered for use in apple and pear orchards as a Lepidopteran pheromone/sex attractant, used to disrupt the mating behaviour of certain moths whose larvae destroy crops.	3.4	7	0	dodecanol; primary alcohol	bacterial metabolite; cosmetic; insect attractant; insecticide; pheromone; plant metabolite
lauryl acetate [no description available]	2	1	0	carboxylic ester
1-tridecanol 1-tridecanol: RN given refers to parent cpd. tridecan-1-ol : A long-chain primary fatty alcohol that is tridecane substituted by a hydroxy group at position 1.. tridecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of thirteen carbon atoms.	1.98	1	0	long-chain primary fatty alcohol; tridecanol	bacterial metabolite; human metabolite; plant metabolite
myristyl alcohol myristyl alcohol: RN given refers to parent cpd. tetradecan-1-ol : A long-chain fatty alcohol that is tetradecane substituted by a hydroxy group at position 1.. tetradecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of fourteen carbon atoms.	1.98	1	0	long-chain primary fatty alcohol; tetradecanol	pheromone; plant metabolite; volatile oil component
stearyl alcohol octadecan-1-ol : A long-chain primary fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of 18 carbon atoms.. octadecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of eighteen carbon atoms.	1.98	1	0	long-chain primary fatty alcohol; octadecanol	algal metabolite; human metabolite; plant metabolite
cyclopentanone [no description available]	2.07	1	0	cyclopentanones	Maillard reaction product
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	2.05	1	0	hexosamine; secondary amino compound
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	3.08	5	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
2-methylbutanol 2-methylbutanol: fragrance; structure in first source. 2-methylbutan-1-ol : A primary alcohol that is isopentane substituted by a hydroxy group at position 1.	2.07	1	0	alkyl alcohol; primary alcohol	Saccharomyces cerevisiae metabolite
dimethyldodecylbenzylammonium dimethyldodecylbenzylammonium: RN given refers to parent cpd. benzododecinium : A quaternary ammonium ion obtained by methylation of N-benzyl-N-methyldodecan-1-amine.	1.98	1	0	quaternary ammonium ion
nitrilotriacetic acid Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)	2.03	1	0	NTA; tricarboxylic acid	carcinogenic agent; nephrotoxic agent
citronellol citronellol: alcohol form of citronellal; found in rose oil; RN given refers to parent cpd without isomeric designation; structure. citronellol : A monoterpenoid that is oct-6-ene substituted by a hydroxy group at position 1 and methyl groups at positions 3 and 7.. insect repellent : An insecticide that acts as a repellent to insects.	3.41	7	0	monoterpenoid	plant metabolite
1-nonanol nonanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of nine carbon atoms.. nonan-1-ol : A nonanol that is nonane substituted by a hydroxy group at position 1. It has been isolated as a component of volatile oils from plants like Hordeum vulgare.	1.98	1	0	nonanol; primary alcohol	antifungal agent; flavouring agent; plant metabolite; volatile oil component
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	7.06	1	0	penicillin allergen; penicillin	antibacterial drug
citronellyl acetate citronellyl acetate: RN given refers to cpd without isomeric designation. citronellol acetate : A monoterpenoid that is the acetate ester of citronellol. It has been isolated from Citrus hystrix.	2.1	1	0	acetate ester; monoterpenoid	plant metabolite
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.73	3	0	catechin	antioxidant; plant metabolite
perylene Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.	2.07	1	0	ortho- and peri-fused polycyclic arene; perylenes
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.01	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.05	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.77	3	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.07	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.95	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.11	1	0	diazine; pyrazines	Daphnia magna metabolite
benzoylarginine-2-naphthylamide Benzoylarginine-2-Naphthylamide: An enzyme substrate which permits the measurement of peptide hydrolase activity, e.g. trypsin and thrombin. The enzymes liberate 2-naphthylamine, which is measured by colorimetric procedures.. N-{5-carbamimidamido-1-[(naphthalen-2-yl)amino]-1-oxopentan-2-yl}benzamide : A member of the class of N-(2-naphthyl)carboxamides that is 5-carbamimidamido-N-(naphthalen-2-yl)pentanamide in which one of the hydrogens at position 2 has been replaced by a benzamido group.	1.96	1	0	arginine derivative; benzamides; N-(2-naphthyl)carboxamide
diazomethane Diazomethane: A diazonium compound with the formula CH2N2.. diazomethane : The simplest diazo compound, in which a diazo group is attached to a methylene group.	2.39	2	0	diazo compound	alkylating agent; antineoplastic agent; carcinogenic agent; poison
fluorobenzenes Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.	2.08	1	0	monofluorobenzenes	NMR chemical shift reference compound
glycocholic acid Glycocholic Acid: The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed.. glycocholic acid : A bile acid glycine conjugate having cholic acid as the bile acid component.. glycocholate : A cholanic acid conjugate anion that is the conjugate base of glycocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.06	1	0	bile acid glycine conjugate	human metabolite
fusarium Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.	4.04	4	0
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.02	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
carvacrol carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).	2.11	1	0	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
4-hydroxyphenylethanol 4-hydroxyphenylethanol: in chest gland secretion of galagos. 2-(4-hydroxyphenyl)ethanol : A phenol substituted at position 4 by a 2-hydroxyethyl group.	6.67	20	0	phenols	anti-arrhythmia drug; antioxidant; cardiovascular drug; fungal metabolite; geroprotector; plant metabolite; protective agent
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.03	1	0	thiazolidine
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	1.98	1	0	abietane diterpenoid; monocarboxylic acid	plant metabolite
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.02	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
tryptophol tryptophol : An indolyl alcohol that is ethanol substituted by a 1H-indol-3-yl group at position 2.	9.14	4	0	indolyl alcohol	auxin; plant metabolite; Saccharomyces cerevisiae metabolite
chamazulene chamazulene: structure	2.07	1	0	sesquiterpenoid
perillyl alcohol perillyl alcohol: inhibits geranylgeranyl transferase; structure in first source. perillyl alcohol : A limonene monoterpenoid consists of a cyclohexene ring substituted by a hydroxymethyl and a prop-1-en-2-yl group at positions 1 and 4 respectively. It is a constituent of a variety of essential oils including lavender.	7.41	2	0	limonene monoterpenoid	plant metabolite; volatile oil component
maleimide [no description available]	2.6	1	0	dicarboximide; maleimides	EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.06	1	0	dialdehyde	biomarker
3-hexen-1-ol 3-hexen-1-ol: RN given refers to (Z)-isomer; a green odor chemical. hex-3-en-1-ol : A primary alcohol that is hex-3-ene substituted by a hydroxy group at position 1.	2.44	2	0	alkenyl alcohol; homoallylic alcohol; primary alcohol; volatile organic compound	plant metabolite
myristic acid Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.	2.91	4	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
n-hexadecane n-hexadecane: structure. hexadecane : A straight-chain alkane with 16 carbon atoms. It is a component of essential oil isolated from long pepper.	2.04	1	0	long-chain alkane	non-polar solvent; plant metabolite; volatile oil component
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	2.48	2	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.48	2	0	phenoxazine
prenol [no description available]	3.81	3	0	alkenyl alcohol; prenols
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol: structure in first source. 4-terpineol : A terpineol that is 1-menthene carrying a hydroxy substituent at position 4.	2.42	2	0	terpineol; tertiary alcohol	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiparasitic agent; apoptosis inducer; plant metabolite; volatile oil component
6-methylsalicylic acid 6-methylsalicylic acid: structure. 6-methylsalicylic acid : A monohydroxybenzoic acid that is salicylic acid in which the hydrogen ortho to the carboxylic acid group is substituted by a methyl group.	1.98	1	0	monohydroxybenzoic acid	Penicillium metabolite; plant metabolite
terpinolene [no description available]	1.98	1	0	p-menthadiene	insect repellent; plant metabolite; sedative; volatile oil component
diphenylamine Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.	2.04	1	0	aromatic amine; bridged diphenyl fungicide; secondary amino compound	antifungal agrochemical; antioxidant; carotogenesis inhibitor; EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor; ferroptosis inhibitor; radical scavenger
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	3.28	6	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
2-hexanol hexan-2-ol : A hexanol in which the hydroxy group is at position 2.	1.98	1	0	hexanol; secondary alcohol	human metabolite; plant metabolite; semiochemical
2-nonanol 2-nonanol: from purple and yellow passion fruits. nonan-2-ol : A secondary alcohol that is nonane substituted by a hydroxy group at position 2.	1.98	1	0	nonanol; secondary alcohol	bacterial metabolite; flavouring agent; pheromone; plant metabolite; rat metabolite; volatile oil component
homoserine homoserine : An alpha-amino acid that is glycine substituted at the alpha-position by a 2-hydroxyethyl group.. L-homoserine : The L-enantiomer of homoserine.	2.44	2	0	amino acid zwitterion; homoserine	algal metabolite; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
ethylnitrosourea Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.	2.02	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; genotoxin; mutagen
dodecylamine dodecylamine: RN given refers to parent cpd	2	1	0	primary aliphatic amine
3-hydroxy-1-benzopyran-2-one 3-hydroxycoumarin: Photoprotective from sea urchin gametes and embryonic cells; structure in first source. hydroxycoumarin : Any coumarin carrying at least one hydroxy substituent.	2.1	1	0	hydroxycoumarin
deoxycytidine [no description available]	6.36	4	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytidine diphosphate choline Cytidine Diphosphate Choline: Donor of choline in biosynthesis of choline-containing phosphoglycerides.	3.8	3	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
rhodamine 6g rhodamine 6G: RN given refers to HCl	2.06	1	0
fenchone, (+-)-isomer fenchone: RN given refers to cpd with unspecified isomeric designation. fenchone : A carbobicyclic compound that is fenchane in which the hydrogens at position 2 are replaced by an oxo group. It is a component of essential oil from fennel (Foeniculum vulgare).	2.06	1	0	carbobicyclic compound; cyclic terpene ketone; fenchane monoterpenoid	plant metabolite
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	3.67	9	0
beta-pinene beta-pinene: alpha-pinene is also available. beta-pinene : An isomer of pinene with an exocyclic double bond. It is a component of essential oils from many plants.	2.42	2	0	pinene	plant metabolite
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	3.5	7	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.44	2	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
s,n,n'-tripropylthiocarbamate Reward: An object or a situation that can serve to reinforce a response, to satisfy a motive, or to afford pleasure.. vernolate : A monounsaturated fatty acid anion that is the conjugate base of vernolic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.21	1	0	tertiary amine
alpha-terpineol terpineol : A family of monoterpenols that have a p-menthane skeleton containing one double bond and bearing a single hydroxy substituent.	2.43	2	0	terpineol	plant metabolite
hydroxyphenytoin hydroxyphenytoin: main metabolite of diphenylhydantoin; reduces Na(+) inhibition at high Na:K ratios; RN given refers to cpd without isomeric designation; structure. 4-hydroxyphenytoin : A imidazolidine-2,4-dione that consists of hydantoin bearing phenyl and 4-hydroxyphenyl substituents at position 5.	2.06	1	0	imidazolidine-2,4-dione; phenols	metabolite
2-(dimethylamino)ethyl methacrylate 2-(dimethylamino)ethyl methacrylate: reducing agent; structure given in first source	2.11	1	0
sabinene sabinene: RN given refers to cpd without isomeric designation. sabinene : A thujene that is a bicyclic monoterpene isolated from the essential oils of various plant species.	2.11	1	0	thujene	plant metabolite
mannose mannopyranose : The pyranose form of mannose.	1.94	1	0	D-aldohexose; D-mannose; mannopyranose	metabolite
dithiothreitol 1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.	1.98	1	0	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
ecdysone [no description available]	4.14	5	0	14alpha-hydroxy steroid; 22-hydroxy steroid; 25-hydroxy steroid; 2beta-hydroxy steroid; 3beta-sterol; 6-oxo steroid; ecdysteroid	prohormone
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.1	1	0	2-phenylcyclopropan-1-amine
2-octanol 2-octanol: RN given refers to cpd without isomeric designation. octan-2-ol : An octanol carrying the hydroxy group at position 2.	1.98	1	0	octanol; secondary alcohol	plant metabolite; volatile oil component
vantocil polihexanide: RN given refers to parent cpd	2.04	1	0
iodinated glycerol iodinated glycerol: secretolytic agent; RN given refers to cpd without iodine locant	4.3	2	2	dioxolane
limonene Limonene: A naturally-occurring class of MONOTERPENES which occur as a clear colorless liquid at room temperature. Limonene is the major component in the oil of oranges which has many uses, including as flavor and fragrance. It is recognized as safe in food by the Food and Drug Administration (FDA).. limonene : A monoterpene that is cyclohex-1-ene substituted by a methyl group at position 1 and a prop-1-en-2-yl group at position 4 respectively.	2.52	2	0	cycloalkene; p-menthadiene	human metabolite
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	3.04	5	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	2.71	3	0	copper group element atom; elemental silver	Escherichia coli metabolite
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.04	1	0	manganese group element atom
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.46	2	0	titanium group element atom
cadmium Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.	7.17	1	0	cadmium molecular entity; zinc group element atom
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	2.03	1	0	N-acetyl-D-glucosamine	epitope
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
isopentenyladenosine Isopentenyladenosine: N(6)-[delta(3)-isopentenyl]adenosine. Isopentenyl derivative of adenosine which is a member of the cytokinin family of plant growth regulators.. N(6)-(Delta(2)-isopentenyl)adenosine : A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group.	2.9	4	0	N-ribosyl-N(6)-isopentenyladenine; nucleoside analogue	antineoplastic agent; plant growth regulator; plant metabolite
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	4.44	7	0	dihydrogen
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	1.94	1	0	diatomic chlorine; gas molecular entity	bleaching agent
nitrous acid Nitrous Acid: Nitrous acid (HNO2). A weak acid that exists only in solution. It can form water-soluble nitrites and stable esters. (From Merck Index, 11th ed)	2.03	1	0	nitrogen oxoacid
ozone Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.	1.94	1	0	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
cadmium chloride Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.	2.02	1	0	cadmium coordination entity
4-chloro-7-nitrobenzofurazan 4-Chloro-7-nitrobenzofurazan: A benzofuran derivative used as a protein reagent since the terminal N-NBD-protein conjugate possesses interesting fluorescence and spectral properties. It has also been used as a covalent inhibitor of both beef heart mitochondrial ATPase and bacterial ATPase.. 4-chloro-7-nitrobenzofurazan : A benzoxadiazole that is 2,1,3-benzoxadiazole which is substituted at position 4 by chlorine and at position 7 by a nitro group.	2.02	1	0	benzoxadiazole; C-nitro compound; organochlorine compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.6.1.3 (adenosinetriphosphatase) inhibitor; fluorescent probe; fluorochrome
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	2	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
3-carene 3-carene: RN given refers to cpd without isomeric designation	2.42	2	0	monoterpene
menthone menthone : The trans-stereoisomer of p-menthan-3-one.. (-)-menthone : A menthone that is cyclohexanone substituted by a methyl and an isopropyl group at positions 5 and 2 respectively (the 2S,5R-stereoisomer).	2.03	1	0	menthone
tiletamine hydrochloride Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.	2.17	1	0
phytanic acid Phytanic Acid: A 20-carbon branched chain fatty acid. In phytanic acid storage disease (REFSUM DISEASE) this lipid may comprise as much as 30% of the total fatty acids of the plasma. This is due to a phytanic acid alpha-hydroxylase deficiency.. phytanic acid : A branched-chain saturated fatty acid consisting of hexadecanoic acid carrying methyl substituents at positions 3, 7, 11 and 15.	2.31	1	0	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid
ferric nitrilotriacetate ferric nitrilotriacetate: induces diabetes in animals (iron loading)	2.03	1	0	iron chelate	carcinogenic agent; mutagen
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	3.1	5	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
fluorides [no description available]	4.39	6	0	halide anion; monoatomic fluorine
stannic oxide tin dioxide : A tin oxide compound consisting of tin(IV) covalently bound to two oxygen atoms.	2.6	1	0	tin oxide
geosmin geosmin: earthy smelling cpd from sediment in Lake Biwa; structure. (-)-geosmin : The (-)-stereoisomer of geosmin, having 4S,4aS,8aR configuration.	6.97	1	0	geosmin
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	2.4	2	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	5.98	27	1	benzenes; phenyl acetates
chloroprene Chloroprene: Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.	2.46	2	0	chloroolefin
alkenes [no description available]	4.51	25	0
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.42	2	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
azoxymethane Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.	2.01	1	0
adenosine diphosphate ribose Adenosine Diphosphate Ribose: An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins.	1.98	1	0	ADP-sugar	Escherichia coli metabolite; mouse metabolite
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.13	1	0	penicillin allergen; penicillin	antibacterial drug
7-ethoxycoumarin 7-ethoxycoumarin : A member of the class of coumarins that is umbelliferone in which the hydroxy group at position 7 is replaced by an ethoxy group.	2.02	1	0	aromatic ether; coumarins
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.58	8	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2	1	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.31	1	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
permethrin hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141	2.11	1	0	cyclopropanecarboxylate ester; cyclopropanes	agrochemical; ectoparasiticide; pyrethroid ester acaricide; pyrethroid ester insecticide; scabicide
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	10.93	40	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.62	9	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	9.18	6	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.03	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	7.84	3	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	6.36	4	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
atorvastatin [no description available]	2.94	4	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.06	1	0
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	7.01	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
isostearyl alcohol 16-methylheptadecan-1-ol : A long-chain primary fatty alcohol that is heptadecan-1-ol substituted by a hydroxy group at position 1 and a methyl group at position 16.	2.02	1	0	long-chain primary fatty alcohol
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.67	3	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.05	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.45	2	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
25-hydroxycholesterol [no description available]	2.42	2	0	25-hydroxy steroid; oxysterol	human metabolite
metaperiodate Periodic Acid: A strong oxidizing agent.	1.94	1	0	iodine oxoacid
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	2.51	2	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.92	4	0	1,2,3-triazole
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	3.58	8	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.61	2	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
avarone avarone: antileukemic agent; isolated from Dysidea avara	2.02	1	0
polygodial [no description available]	1.98	1	0	aldehyde
nagilactone c nagilactone C: norditerpene lactone isolated from leaves of Podocarpus; structure	1.98	1	0
4-nitrophenyl palmitate p-nitrophenyl palmitate : A palmitate ester obtained by condensation of the carboxy group of palmitic acid with the phenolic hydroxy group of p-nitrophenol.	2.03	1	0	C-nitro compound; hexadecanoate ester
rosiglitazone [no description available]	2.03	1	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
3,7-dimethyl-7-octen-1-ol Geranium: A plant genus of the family GERANIACEAE. Geranium is also used as a common name for PELARGONIUM.	1.94	1	0
coenzyme a [no description available]	2.35	2	0	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
acetyl methyl tetramethyl tetralin acetyl methyl tetramethyl tetralin: musk fragrance; structure given in first source	2.05	1	0	tetralins
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.21	1	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
beta-eudesmol beta-eudesmol: found in Atractylodes and other plants; RN given refers to (2R-(2alpha,4aalpha,8abeta))-isomer. beta-eudesmol : A carbobicyclic compound that is trans-decalin substituted at positions 2, 4a, and 8 by 2-hydroxypropan-2-yl, methyl and methylidene groups, respectively (the 2R,4aR,8aS-diastereoisomer).	2.1	1	0	carbobicyclic compound; eudesmane sesquiterpenoid; tertiary alcohol	volatile oil component
7-ketocholesterol 7-ketocholesterol: inhibits uptake of cholesterol in rabbit aorta. 7-ketocholesterol : A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7.	2.05	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; 7-oxo steroid; cholestanoid	neuroprotective agent
hydroxyisohexyl 3-cyclohexene carboxaldehyde hydroxyisohexyl 3-cyclohexene carboxaldehyde: structure in first source	2.74	3	0
elemol elemol: monocyclic sespuiterpenoid tertiary alcohol; RN given refers to (1R-(1alpha,3alpha,4beta))-isomer; structure in first source. elemol : A sesquiterpenoid that is isopropanol which is substituted at position 2 by a (3S,4S)-3-isopropenyl-4-methyl-4-vinylcyclohexyl group.	2.06	1	0	olefinic compound; sesquiterpenoid; tertiary alcohol	fragrance; plant metabolite
diploptene diploptene: biosynthesized in a cell-free system from Acetobacter pasteurianum in the presence of squalene. hop-22(29)-ene : A triterpene consisting of hopane having a C=C double bond at the 22(29)-position.	2.41	1	0	triterpene
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	2.9	4	0	6-isopentenylaminopurine	cytokinin
spathulenol [no description available]	2.1	1	0	carbotricyclic compound; olefinic compound; sesquiterpenoid; tertiary alcohol	anaesthetic; plant metabolite; vasodilator agent; volatile oil component
alpha-eudesmol alpha-eudesmol: RN refers to (2alpha,4aalpha,8abeta)-isomer; from Juniperus virginiana; inhibits omega-agatoxin IVA-sensitive Ca2+ currents and synaptosomal Ca2+ uptake; structure in first source. alpha-eudesmol : A eudesmane sesquiterpenoid in which the eudesmane skeleton carries a hydroxy substituent at C-11 and has a double bond between C-3 and C-4.	2.1	1	0	eudesmane sesquiterpenoid; octahydronaphthalenes; tertiary alcohol	volatile oil component
totarol totarol: structure given in first source; isolated from the bark of Podocarpus nagi	1.98	1	0	diterpenoid	metabolite
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.03	1	0
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	2.03	1	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
sn 38 SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.	2.06	1	0	delta-lactone; phenols; pyranoindolizinoquinoline; tertiary alcohol	antineoplastic agent; apoptosis inducer; drug metabolite; EC 5.99.1.2 (DNA topoisomerase) inhibitor
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.05	1	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate: a surfactant; structure given in first source	1.99	1	0	1,1-diunsubstituted alkanesulfonate
22-hydroxycholesterol [no description available]	2	1	0	cholanoid
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	2	1	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.07	1	0
valerates Valerates: Derivatives of valeric acid, including its salts and esters.	2.35	2	0	short-chain fatty acid anion; straight-chain saturated fatty acid anion	plant metabolite
di-n-desethylamiodarone di-N-desethylamiodarone: amiodarone metabolite in dogs; structure given in first source	3.23	1	0
hernandulcin hernandulcin: sesquiterpene 1000 times sweeter than sucrose from sweet plant Lippia dulcis Trev.; structure given in first source	2.25	1	0	sesquiterpenoid
pseudomonas aeruginosa autoinducer Pseudomonas aeruginosa autoinducer: autoinducer required for expression of Pseudomonas aeruginosa virulence genes; structure given in first source. N-(3-oxododecanoyl)homoserine lactone : A N-acyl homoserine lactone that is the monocarboxylic acid amide arising from formal condensation of homoserine lactone with 3-oxododecanoic acid.	2.44	2	0	N-acyl homoserine lactone
ym 529 YM 529: inhibits osteoclastic bone resorption; structure given in first source	2.01	1	0
b 581 B 581: blocks farnesylated but not geranylgeranylated or myristylated, oncogenic Ras signaling & transformation. B 581 : A dipeptide obtained from the tetrapeptide Cys-Val-Phe-Met by reduction of the amide carbonyl groups of the Cys and Val residues.	1.98	1	0	dipeptide	EC 2.5.1.58 (protein farnesyltransferase) inhibitor; peptidomimetic
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	7.77	3	0	beta-lactam antibiotic allergen; beta-lactam
phytol [no description available]	2.68	3	0
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.06	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
lonafarnib lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.	2.01	1	0	4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	2.02	1	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
farnesylacetic acid farnesylacetic acid: RN given refers to cpd without isomeric designation	4.13	16	0
camphora camphora: a component of Guanxingao, a kind of traditional Chinese rubber electuary medicine which is able to either cure or guard against coronary heart disease and angina pectoris. (R)-camphor : The (R)- enantiomer of camphor.	1.98	1	0	camphor
tipifarnib [no description available]	2.03	1	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
t-cadinol T-cadinol: extract of scented myrrh; RN given refers to (1S-(1alpha,4alpha,4aalpha,8abeta)-isomer; RN for cpd without isomeric designation not avail 3/92; structure given in first source. tau-cadinol : A cadinane sesquiterpenoid that is cadin-4-ene carrying a hydroxy substituent at position 10.	2.1	1	0	cadinane sesquiterpenoid; carbobicyclic compound; octahydronaphthalenes; tertiary alcohol	plant metabolite; volatile oil component
org 31710 Org 31710: structure given in first source; progestational hormone antagonist	2.03	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.6	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	1.98	1	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
isopulegol isopulegol: isolated from Mentha cardiaca structure in first source	2.1	1	0	p-menthane monoterpenoid	metabolite
albicanol albicanol: structure in first source	2.01	1	0	carbobicyclic compound; homoallylic alcohol; primary alcohol; sesquiterpenoid	antifeedant; antifungal agent; antineoplastic agent; fungal metabolite; mammalian metabolite; marine metabolite; plant metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.03	1	0	amino acid zwitterion; angiotensin II	human metabolite
sb 203580 [no description available]	2	1	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sk&f 99085 [no description available]	2	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	4.07	15	0	divalent inorganic anion; phosphite ion
nickel monoxide [no description available]	2.6	1	0
l 734005 5-chloro-3-phenylthioindole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase	2.11	1	0
cohumulone cohumulone: do not confuse with the 2,5-cyclohexadiene positional isomer by the same name; structure in first source	2.17	1	0	secondary alpha-hydroxy ketone
taspine taspine: RN given refers to parent cpd; structure	2	1	0
sitosterol, (3beta)-isomer Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.	1.98	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
erythritol [no description available]	2.13	1	0	butane-1,2,3,4-tetrol	antioxidant; human metabolite; plant metabolite
equilin Equilin: An estrogenic steroid produced by HORSES. It has a total of four double bonds in the A- and B-ring. High concentration of euilin is found in the URINE of pregnant mares.	1.96	1	0	17-oxo steroid; 3-hydroxy steroid
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.08	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
lanosterol [no description available]	8.21	6	0	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
a-130a [no description available]	2.1	1	0
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	2.13	1	0
bortezomib [no description available]	7.11	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.06	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
cimadronate cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source	2.41	2	0
leptomycin b [no description available]	2.07	1	0
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	1.95	1	0
canavanine L-canavanine : A non-proteinogenic L-alpha-amino acid that is L-homoserine substituted at oxygen with a guanidino (carbamimidamido) group. Although structurally related to L-arginine, it is non-proteinogenic.	2	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	phytogenic insecticide; plant metabolite
mevalonic acid Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.	9.66	112	0	3,5-dihydroxy-3-methylpentanoic acid
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	2.13	1	0	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
epiglucan epiglucan: a highly side-chain/branched alkali-insoluble cell wall glucan from fungus such as Epicoccum nigrum, Botrytis cinerea, ascomycetes & basidiomycetes; also isolated S-4001 from Lei Wan (polyporus mylitiae), HA-beta-glucan from mushroom Pleutotus ostreatus (Fr.) Quel., and translam from seaweed Laminaria cichorioides; with commercially important functional properties including emulsification and friction reduction.	2.49	2	0
pantetheine Pantetheine: An intermediate in the pathway of coenzyme A formation in mammalian liver and some microorganisms.. pantetheine : An amide obtained by formal condensation of the carboxy group of pantothenic acid and the amino group of cysteamine.	2.1	1	0	pantetheines; thiol	human metabolite; metabolite; mouse metabolite
inositol 1,4,5-trisphosphate Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.	1.99	1	0	myo-inositol trisphosphate	mouse metabolite
desmosterol Desmosterol: An intermediate in the synthesis of cholesterol.. desmosterol : A cholestanoid that is cholesta-5,24-diene substituted by a beta-hydroxy group at position 3. It is an intermediate metabolite obtained during the synthesis of cholesterol.	1.99	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C27-steroid; cholestanoid	human metabolite; mouse metabolite
(+)-limonene (4R)-limonene : An optically active form of limonene having (4R)-configuration.	1.98	1	0	limonene	plant metabolite
(+)-delta-cadinene delta-cadinene: has antineoplastic activity; structure in first source. delta-cadinene : A member of the cadinene family of sesquiterpenes in which the double bonds are located at the 4-4a and 7-8 positions, and in which the isopropyl group at position 1 is cis to the hydrogen at the adjacent bridgehead carbon (position 8a).. (+)-delta-cadinene : A member of the cadinene family of sesquiterpenes in which the double bonds are located at the 4-4a and 7-8 positions, and in which the isopropyl group at position 1 is cis to the hydrogen at the adjacent bridgehead carbon (the 1S,8aR-enantiomer).	2.42	2	0	cadinene; delta-cadinene
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.31	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
hyperforin hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.	2.05	1	0
phalloidine Phalloidine: Very toxic polypeptide isolated mainly from AMANITA phalloides (Agaricaceae) or death cup; causes fatal liver, kidney and CNS damage in mushroom poisoning; used in the study of liver damage.. phalloidin : A homodetic bicyclic heptapeptide having a sulfide bridge.	2.01	1	0	homodetic cyclic peptide
picrotoxinin [no description available]	2.01	1	0	epoxide; gamma-lactone; organic heteropentacyclic compound; picrotoxane sesquiterpenoid; tertiary alcohol	GABA antagonist; plant metabolite; serotonergic antagonist
bisabolol Kamillosan: drug combination containing chamomile and bisabolol; used to treat dermatitis	2	1	0	sesquiterpenoid
alpha bitter acid humulon: antibiotic from hops; structure	2.17	1	0	aromatic ketone; cyclic ketone; diketone; tertiary alpha-hydroxy ketone; triol	antibacterial drug; antioxidant; cyclooxygenase 2 inhibitor; metabolite
1-alpha-terpineol (S)-(-)-alpha-terpineol : The (S)-enantiomer of alpha-terpineol.	2.71	3	0	alpha-terpineol	plant metabolite
2-c-methylerythritol 4-phosphate 2-C-methylerythritol 4-phosphate: structure in first source	2.13	1	0	tetritol phosphate	Escherichia coli metabolite
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	1.98	1	0	tripeptide
pyochelin pyochelin: phenolic iron-binding cpd from Pseudomonas aeruginosa; promotes the growth of bacterium when added to iron-deficient media. pyochelin : A member of the class of thiazolidines that is (4R)-3-methyl-1,3-thiazolidine-4-carboxylic acid which is substituted at position 2 by a (4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl group. A siderophore that is produced by Pseudomonas aeruginosa (via condensation of salicylic acid and two molecules of cysteine) as a mixture of two easily interconvertible diastereoisomers, pyochelin I (major) and pyochelin II (minor). The enantiomeric compounds, enant-pyochelin, are produced by Pseudomonas fluorescens.	2.11	1	0	monocarboxylic acid; phenols; thiazolidines	metabolite; siderophore
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.82	2	0	cyclodextrin
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	2.35	2	0	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.11	1	0	cinnamic acid	plant metabolite
retinylamine retinylamine: structure	2.04	1	0
ergosterol [no description available]	9.77	9	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.12	5	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
3-hydroxy-3-methylglutaryl-coenzyme a 3-hydroxy-3-methylglutaryl-coenzyme A: RN given refers to cpd without isomeric designation. 3-hydroxy-3-methylglutaryl-CoA : An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.. (3S)-3-hydroxy-3-methylglutaryl-CoA : A 3-hydroxy-3-methylglutaryl-CoA where the 3-hydroxy-3-methylglutaryl component has (S)-configuration.	2.06	1	0	3-hydroxy-3-methylglutaryl-CoA; 3-hydroxy fatty acyl-CoA	human metabolite; mouse metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.04	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	2.71	3	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.46	2	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
farnesyl pyrophosphate farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation. 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate.	10.04	41	0	farnesyl diphosphate	Escherichia coli metabolite; mouse metabolite
geranyl pyrophosphate geranyl pyrophosphate: RN given refers to (E)-isomer. geranyl diphosphate : The diphosphate of the polyprenol compound geraniol.	3.12	5	0	polyprenyl diphosphate	Escherichia coli metabolite; mouse metabolite
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.69	3	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	1.94	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
lycopene [no description available]	2.21	1	0	acyclic carotene	antioxidant; plant metabolite
geranylgeranyl pyrophosphate geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.	3.41	7	0	geranylgeranyl diphosphate	mouse metabolite
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.06	1	0	prostaglandins D	human metabolite; mouse metabolite
alitretinoin Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.	2.45	2	0	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	1.99	1	0	actinomycin	mutagen
aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.	2	1	0	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	3.23	1	0	quinolines
l 743,872 [no description available]	3.24	5	0
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	7.86	3	0	antibiotic antifungal drug; echinocandin	antiinfective agent
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	2.06	1	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
sodium acetate, anhydrous Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.	2	1	0	organic sodium salt	NMR chemical shift reference compound
mesoxalonitrile mesoxalonitrile: minor descriptor (75-83); on-line & Index Medicus search NITRILES (75-83)	2.05	1	0	alpha-ketonitrile; nitrile
spathulenol spathulenol: sesquiterpene alcohol isolated from essential oils of Artemisia vulgaris L. & Artemisia dracunculus L.. spathulenol : A tricyclic sesquiterpenoid that is 4-methylidenedecahydro-1H-cyclopropa[e]azulene carrying three methyl substituents at positions 1, 1 and 7 as well as a hydroxy substituent at position 7.	2.04	1	0
alpha-asarone asarone: structure in Merck Index, 9th ed, #847. asarone : A phenylpropanoid that is benzene substituted by methoxy groups at positions 1, 2 and 4 and a propen-1-yl group at position 5. It has been isolated from Acorus.. alpha-asarone : The trans-isomer of asarone.	1.98	1	0	asarone	anticonvulsant; GABA modulator
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	7.87	3	0	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
anethole anethole: an isomer of estragole; structurally similar to CAPSAICIN; has some neurological and insecticidal and skin absorption effects; RN given refers to unspecified stereoisomer. anethole : A monomethoxybenzene that is methoxybenzene substituted by a prop-1-en-1-yl group at position 4.. trans-anethole : The trans-stereoisomer of anethole.	2.44	2	0	anethole	flavouring agent
geraniol [no description available]	5.91	32	0	3,7-dimethylocta-2,6-dien-1-ol; monoterpenoid; primary alcohol	allergen; fragrance; plant metabolite; volatile oil component
glycosides [no description available]	2.25	1	0
isomethyleugenol Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)	3.84	12	0	isomethyleugenol
isosafrole isosafrole: RN given refers to cpd without isomeric designation	1.98	1	0	benzodioxoles
citral citral: Xref geranial: geraniol is also available; Xref neral: nerol is also available; vitamin A antagonist; oxygenated monoterpene; inhibits cytosolic dehydrogenases; structure. citral : An enal that consists of octa-2,6-dienal bearing methyl substituents at positions 3 and 7. A mixture of the two geometric isomers geranial and neral, it is the major constituent (75-85%) of oil of lemon grass, the volatile oil of Cymbopogon citratus, or of C. flexuosus. It also occurs in oils of verbena, lemon, and orange.	3.15	5	0	enal; monoterpenoid; polyprenal	plant metabolite; volatile oil component
beta-ionone beta-ionone: stimulator of carotenogenesis; carotenoid inhibitor; intermediate in synthesis of Vit A; RN given refers to cpd without isomeric designation; structure. beta-ionone : An ionone that is but-3-en-2-one substituted by a 2,6,6-trimethylcyclohex-1-en-1-yl group at position 4.	2.08	1	0	ionone	antioxidant; fragrance
retinaldehyde Retinaldehyde: A diterpene derived from the carotenoid VITAMIN A which functions as the active component of the visual cycle. It is the prosthetic group of RHODOPSIN (i.e., covalently bonded to ROD OPSIN as 11-cis-retinal). When stimulated by visible light, rhodopsin transforms this cis-isomer of retinal to the trans-isomer (11-trans-retinal). This transformation straightens-out the bend of the retinal molecule and causes a change in the shape of rhodopsin triggering the visual process. A series of energy-requiring enzyme-catalyzed reactions convert the 11-trans-retinal back to the cis-isomer.. all-trans-retinal : A retinal in which all four exocyclic double bonds have E- (trans-) geometry.	2.04	1	0	retinal; vitamin A	gap junctional intercellular communication inhibitor; human metabolite; mouse metabolite
squalene Addavax: an oil-water nanoemulsion and adjuvant containing squalene, Tween 80, and sorbitane trioleate	12.26	53	0	triterpene	human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
isoliquiritigenin [no description available]	2.04	1	0	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
xanthoangelol xanthoangelol: from Angelica keiskei; structure given in first source; RN given refers to (E,E)-isomer	2.04	1	0
nerol nerol : The (2Z)-stereoisomer of 3,7-dimethylocta-2,6-dien-1-ol. It has been isolated from the essential oils from plants like lemon grass.	2.1	1	0	3,7-dimethylocta-2,6-dien-1-ol	fragrance; plant metabolite; volatile oil component
flavin-adenine dinucleotide Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)	2.39	2	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	4.69	30	0	diphosphate ion
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.44	2	0	benzamides
nsc 4347 NSC 4347: structure in first source	2.46	2	0
r 59949 R 59949: diacylglycerol kinase inhibitor	2.01	1	0	diarylmethane
sesquiterpenes [no description available]	11.86	84	0
isoeugenol trans-isoeugenol : The trans-stereoisomer of isoeugenol.	2.21	1	0	isoeugenol	plant metabolite
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.1	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
thiazoline-2-thione thiazoline-2-thione: carboxyl-activating reagent in peptide synthesis	2.03	1	0
urb 597 cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester: a fatty acid amide hydrolase inhibitor; structure in first source	2.05	1	0	biphenyls
terbinafine [no description available]	2.89	3	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
geranyl acetate geranyl acetate: constituted about 90% of the palmarosa oil. geranyl acetate : A monoterpenoid that is the acetate ester derivative of geraniol.	2.11	1	0	acetate ester; monoterpenoid	plant metabolite
tosylarginine methyl ester Tosylarginine Methyl Ester: Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).	1.96	1	0	guanidines; L-arginine ester; methyl ester; sulfonamide
aurapten aurapten: RN refers to (E)-isomer; structure given in first source. auraptene : A member of the class of coumarins that is umbelliferone in which the phenolic hydrogen has been replaced by a geranyl group. Ii is isolated from several edible fruits and vegetables and exhibits a variety of therapeutic properties.	2.1	1	0	coumarins; monoterpenoid	antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; dopaminergic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; gamma-secretase modulator; gastrointestinal drug; hepatoprotective agent; matrix metalloproteinase inhibitor; neuroprotective agent; plant metabolite; PPARalpha agonist; vulnerary
hexyl cinnamic aldehyde [no description available]	2.43	2	0	cinnamaldehydes
caryophyllene oxide caryophyllene oxide: has butyrylcholinesterase inhibitory activity; structure in first source. epoxide : Any cyclic ether in which the oxygen atom forms part of a 3-membered ring.	2.61	2	0	epoxide	metabolite
umbelliprenin umbelliprenin: RN given refers to cpd with unspecified isomeric designation	2.38	2	0	terpene lactone
8,10-dodecadien-1-ol 8,10-dodecadien-1-ol: isomer of coddling moth sex attractant; RN given refers to (E,E)-isomer, which is codlemone	2.02	1	0
longifolene longifolene: from plant products; RN given refers to (1S-(1alpha,3abeta,4alpha,8abeta))-isomer; structure given in first source	1.98	1	0	longifolene
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	1.94	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
thioacetamide Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.	2.02	1	0	thiocarboxamide	hepatotoxic agent
fumonisin b1 fumonisin B1: isolated from Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting activity; inhibits ceramide synthase. fumonisin B1 : A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.	2.07	1	0	diester; fumonisin; primary amino compound; triol	carcinogenic agent; metabolite
tamoxifen [no description available]	2.44	2	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
nadp [no description available]	4.44	23	0
2-heptyl-3-hydroxy-4-quinolone 2-heptyl-3-hydroxy-4-quinolone: structure in first source. 2-heptyl-3-hydroxy-4-quinolone : A quinolone consisting of quinolin-4(1H)-one carrying a heptyl substituent at position 2 and a hydroxy group at position 3.	2.03	1	0	quinolone	signalling molecule
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
laccase Laccase: A copper-containing oxidoreductase enzyme that catalyzes the oxidation of 4-benzenediol to 4-benzosemiquinone. It also has activity towards a variety of O-quinols and P-quinols. It primarily found in FUNGI and is involved in LIGNIN degradation, pigment biosynthesis and detoxification of lignin-derived products.	2.17	1	0
pica Pica: The persistent eating of non-nutritive substances for a period of at least one month.	2.17	1	0
lithium Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.	2.64	3	0	alkali metal atom
chaetomellic acid a chaetomellic acid A: structure given in first source; an inhibitor of farnesyl-protein transferase	2.4	2	0
rasagiline [no description available]	2.02	1	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
safingol safingol: RN given refers to the (R-(R,S))-isomer	2.07	1	0	amino alcohol
drimenol drimenol: structure in first source. drimenol : A sesquiterpenoid primary alcohol, being methanol in which one of the methyl hydrogens is substituted by a 2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl group.	3.16	1	0	homoallylic alcohol; octahydronaphthalenes; primary alcohol; sesquiterpenoid
farnesylamine farnesylamine: inhibits farnesyl-protein transferase and geranylgeranyl-protein transferase	4.6	8	0
allatostatin 1 allatostatin 1: inhibits juvenile hormone synthesis; from reproductively active females	2.4	2	0
24,25-epoxycholesterol 24,25-epoxycholesterol: Rn given refers to (3alpha,5beta)-isomer; structure given in first source. 24(S),25-epoxycholesterol : A 3beta-hydroxy-Delta(5)-steroid that is desmosterol in which the double bond at position 24-25 has been oxidised to the corresponding epoxide (the 24S diastereoisomer). It is an oxysterol agonist of the liver X receptor.	2.05	1	0	3beta-hydroxy-Delta(5)-steroid; cholestanoid; epoxy steroid	liver X receptor agonist
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	1.99	1	0
homoserine lactone homoserine lactone: a putative signal for starvation in E. coli; structure in first source. homoserinium lactone : The conjugate acid of homoserine lactone; major species at pH 7.3.. homoserine lactone : A butan-4-olide having an amino substituent at the 2-position.	7.73	3	0	ammonium ion derivative; organic cation
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.37	2	0
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.08	1	0	long-chain fatty acid
farnesoic acid farnesoic acid : A methyl-branched, trienoic fatty acid consisting of dodeca-2,6,10-trienoic acid having three methyl substituents at the 3-, 7- and 11-positions.. (2E,6E)-farnesoic acid : A farnesoic acid in which the double bonds at positions 2 and 6 both have E-configuration.	8.65	9	0	farnesoic acid	animal metabolite
methyl farnesoate methyl farnesoate: RN given refers to cpd without isomeric designation. methyl farnesoate : A member of the juvenile hormone family of compounds that is the methyl ester of farnesoic acid. Found in several species of crustaceans.	3.11	5	0	enoate ester; fatty acid methyl ester; juvenile hormone	crustacean metabolite
decaprenoic acid geranoic acid: structure in first source. geranic acid : A polyunsaturated fatty acid that is octa-2,6-dienoic acid bearing two methyl substituents at positions 3 and 7 (the 2E-isomer).	2.01	1	0	alpha,beta-unsaturated monocarboxylic acid; methyl-branched fatty acid; monoterpenoid; polyunsaturated fatty acid	antifungal agent; EC 1.14.18.1 (tyrosinase) inhibitor; melanin synthesis inhibitor; pheromone; plant metabolite
geranylgeranic acid geranylgeranic acid: RN given refers to cpd without isomeric designation. (2E,6E,10E)-geranylgeranic acid : A diterpenoid obtained by formal oxidation of the CH2OH group of (E,E,E)-geranylgeraniol to the corresponding carboxylic acid.	2.75	3	0	alpha,beta-unsaturated monocarboxylic acid; diterpenoid; methyl-branched fatty acid; trienoic fatty acid
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.07	1	0	sphing-4-enine	human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.8	3	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
sterigmatocystin [no description available]	2.07	1	0	sterigmatocystins	metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	5.16	8	0	trihydroxyflavone	antineoplastic agent; metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.1	1	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
undecaprenol undecaprenol: a C55 terpene. all-trans-undecaprenol : A long-chain primary fatty alcohol that is the all-trans-isomer of undecaprenol.	1.96	1	0	long-chain primary fatty alcohol; undecaprenols
vitamin k semiquinone radical vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.	3.97	4	0
11-cis-retinal Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.	3.09	5	0	retinal	chromophore; human metabolite; mouse metabolite
hymecromone Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.	2.06	1	0	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor
farnesal [no description available]	10.41	18	0	farnesal; polyprenal
undecaprenyl pyrophosphate undecaprenyl diphosphate : A polyprenol diphosphate compound having eleven prenyl units with undefined stereochemistry about the double bonds.	2.43	2	0	all-trans-polyprenyl diphosphate; undecaprenyl diphosphate; undecaprenyl phosphate
neurosporene [no description available]	1.99	1	0	acyclic carotene
alpha-linolenic acid linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.	2	1	0	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.51	7	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pyrvinium pyrvinium: RN given refers to parent cpd; synonyms vanquin & vankin refer to pamoate[2:1]; structure in Merck Index, 9th ed, #7810. pyrvinium : A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents.	2.07	1	0	quinolinium ion	anthelminthic drug; antineoplastic agent
azadirachtin azadirachtin A : A member of the family of azadirachtins that is isolated from the neem tree (Azadirachta indica).. azadirachtin : A family of terpenoids isolated from the neem tree (Azadirachta indica).	2	1	0	acetate ester; azadirachtin; cyclic hemiketal; enoate ester; epoxide; methyl ester; organic heterotetracyclic compound; secondary alcohol; tertiary alcohol	hepatoprotective agent
geranylgeraniol (E,E,E)-geranylgeraniol : A geranylgeraniol in which all four double bonds have E- (trans-) geometry.	9.62	77	0	geranylgeraniol
7-hydroxycoumarin 7-oxycoumarin: derivatives have anti-oxidant properties. umbelliferone : A hydroxycoumarin that is coumarin substituted by a hydroxy group ay position 7.	2.1	1	0	hydroxycoumarin	fluorescent probe; food component; plant metabolite
caryophyllene (-)-beta-caryophyllene : A beta-caryophyllene in which the stereocentre adjacent to the exocyclic double bond has S configuration while the remaining stereocentre has R configuration. It is the most commonly occurring form of beta-caryophyllene, occurring in many essential oils, particularly oil of cloves.. beta-caryophyllene : A sesquiterpene with a [7.2.0]-bicyclic structure comprising fused 9- and 4-membered rings, with a trans-ring junction, a trans-double bond between the 4- and 5-positions of the 9-membered ring, a methylidene group at position 9, and methyl groups at positions 3, 11, and 11. The most commonly occurring form is the (1R,9S)-(-)-enantiomer, which is found in many essential oils, particularly clove oil.. cannabinoid : A diverse group of pharmacologically active secondary metabolite characteristic to Cannabis plant as well as produced naturally in the body by humans and animals. Cannabinoids contain oxygen as a part of the heterocyclic ring or in the form of various functional groups. They are subdivided on the basis of their origin.	2.42	2	0	beta-caryophyllene	fragrance; insect attractant; metabolite; non-steroidal anti-inflammatory drug
alpha-farnesene alpha-farnesene: structure given in first source. alpha-farnesene : A farnesene that is 1,3,6,10-tetraene substituted by methyl groups at positions 3, 7 and 11 respectively.. farnesene : A sesquiterpene that is any of the four possible isomers of 3,7,11-trimethyl-1,3,6,10-dodecatetraene (alpha-farnesene) or of the two possible isomers of 7,11-dimethyl-3-methylene-1,6,10-dodecatriene.	2.6	1	0	alpha-farnesene
humulene humulene: structure given in first source. (1E,4E,8E)-alpha-humulene : The (1E,4E,8E)-isomer of alpha-humulene.	2.44	2	0	alpha-humulene
baicalein [no description available]	2.06	1	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
myricetin [no description available]	7.78	3	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
daidzein [no description available]	2.06	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
ginkgolic acid [no description available]	1.98	1	0	hydroxybenzoic acid
coenzyme q10 coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.	2	1	0	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite
gefarnate Gefarnate: A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.	2.65	3	0	organic molecular entity
indomethacin farnesil [no description available]	2	1	0	N-acylindole
plaunotol plaunotol: RN refers to (Z,E,E)-isomer. plaunotol : A diterpenoid that is geranylgeraniol carrying an additional hydroxy substituent at position 18.	2.02	1	0	diterpenoid; primary alcohol	anti-ulcer drug; antibacterial agent; antineoplastic agent; apoptosis inducer; nephroprotective agent; plant metabolite; vulnerary
prednisolone farnesylate prednisolone farnesylate: structure given in first source	3.92	13	0	organic molecular entity
menatetrenone menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration.	1.99	1	0	menaquinone	anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.05	1	0	4-hydroxynon-2-enal; 4-hydroxynonenal
2,4-decadienal (2E,4E)-deca-2,4-dienal : A polyunsaturated fatty aldehyde that is decanal which has undergone formal dehydrogenation to introduce trans- double bonds at the 2-3 and 4-5 positions. A product of lipid peroxidation in cell membranes and a component of cooking oil fumes.	2.04	1	0	polyunsaturated fatty aldehyde	apoptosis inducer; nematicide
menaquinone 6 menaquinone 6: RN given refers to (all-E)-isomer	2.69	3	0
oleyl alcohol oleyl alcohol: structure; RN given refers to cpd without isomeric designation	2.02	1	0	fatty alcohol 18:1; long-chain primary fatty alcohol	metabolite; nonionic surfactant
nerolidol (6E)-nerolidol : A nerolidol in which the double bond at position 6 adopts a trans-configuration.	2.4	2	0	nerolidol
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	1.99	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	4.09	4	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
pyoverdin pyoverdin: a partly cyclic octapeptide linked to a chromophore, derived from 2,3-diamino-6,7-dihydroxyquinoline, which confers color and fluorescence to the molecule; yellow-green pigment produced by Pseudomonas aeruginosa; pyoverdin Pf from P. fluorescens; structure has been determined	2.11	1	0
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	2.01	1	0	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
decaprenoic acid decaprenoic acid: synthetic isoprenoid; RN given refers to cpd without isomeric designation; structure given in first source	2.01	1	0	monoterpenoid
biliverdine [no description available]	2.13	1	0
cinnamyl alcohol cinnamyl alcohol: RN given refers to parent cpd without isomeric designation. (E)-cinnamyl alcohol : The E (trans) stereoisomer of cinnamyl alcohol.. cinnamyl alcohol : A primary alcohol comprising an allyl core with a hydroxy substituent at the 1-position and a phenyl substituent at the 3-position (geometry of the C=C bond unspecified).	2.21	1	0	cinnamyl alcohol	plant metabolite
beta-farnesene beta-farnesene: structure given in first source	7.72	3	0	beta-farnesene
andrographolide [no description available]	2.11	1	0	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite
nerolidol nerolidol: sesquiterpene; RN given refers to cpd without isomeric designation; nerol is also available. nerolidol : A farnesane sesquiterpenoid that is dodeca-1,6,10-triene which carries methyl groups at positions 3, 7 and 11 and a hydroxy group at position 3. It is a natural product that is present in various flowers and plants with a floral odor. Chemically, it exists in two geometric isomers, trans and cis forms. It is widely used in cosmetics (e.g. shampoos and perfumes), in non-cosmetic products (e.g. detergents and cleansers) and also as a food flavoring agent.. (6Z)-nerolidol : A nerolidol in which the double bond at position 6 adopts a cis-configuration.	4.43	20	0	nerolidol
caryophyllene caryophyllene: RN given refers to cpd without isomeric designation; structure given in first source	2.83	3	0
lead Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.	1.94	1	0	carbon group element atom; elemental lead; metal atom	neurotoxin
farnesylthioacetic acid farnesylthioacetic acid: a competitive inhibitor of isoprenylated protein methyltransferase; structure in first source	2.92	4	0
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2	1	0	alkaline earth metal atom; elemental barium
oleylamine oleylamine: promotes fusion of mouse A(9) fibroblasts; RN given refers to parent cpd with unspecified isomeric designation; structure	2.69	3	0
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	2.86	4	0	boron group element atom; elemental aluminium; metal atom
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2.06	1	0	chalcogen; nonmetal atom	macronutrient
geldanamycin [no description available]	3.16	1	0
3,7,11,15-tetramethyl-2-hexadecen-1-ol 3,7,11,15-tetramethyl-2-hexadecen-1-ol: a fragrance ingredient; structure in first source	3.41	1	0
methoprene Methoprene: Juvenile hormone analog and insect growth regulator used to control insects by disrupting metamorphosis. Has been effective in controlling mosquito larvae.	3.74	3	0	isopropyl 11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; isopropyl ester	juvenile hormone mimic
germacrene d germacrene D: RN in 9th CI Form Index for unspecified stereoisomer: 37839-63-7	2.08	1	0
demethylmenaquinone [no description available]	1.96	1	0	2-demethylmenaquinone
diphenylhexatriene Diphenylhexatriene: A fluorescent compound that emits light only in specific configurations in certain lipid media. It is used as a tool in the study of membrane lipids.	1.99	1	0	alkatriene	fluorochrome
cytochalasin a [no description available]	2.05	1	0	cytochalasin
dimyristoylphosphatidylcholine 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).	7.93	4	0	1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester	antigen; mouse metabolite
ecdysterone Ecdysterone: A steroid hormone that regulates the processes of MOLTING or ecdysis in insects. Ecdysterone is the 20-hydroxylated ECDYSONE.. 20-hydroxyecdysone : An ecdysteroid that is ecdysone substituted by a hydroxy group at position 20.	2.36	2	0	14alpha-hydroxy steroid; 20-hydroxy steroid; 22-hydroxy steroid; 25-hydroxy steroid; 2beta-hydroxy steroid; 3beta-sterol; ecdysteroid; phytoecdysteroid	animal metabolite; plant metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	10.23	16	0	cysteinium	fundamental metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	1.94	1	0	carbon group element atom; metalloid atom; nonmetal atom
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	1.94	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
s-trans,trans-farnesylthiosalicylic acid farnesylthiosalicylic acid: structure in first source	13.29	157	5	sesquiterpenoid
solanesol solanesol : A nonaprenol that is hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol substituted by 9 methyl groups at positions 3, 7, 11, 15, 19, 23, 27, 31 and 35 (the all-trans0stereoisomer).	3.8	3	0	nonaprenol; primary alcohol	plant metabolite
1,5-bis(2-methoxy-4-nitro-5-sulfophenyl)-3-((phenylamino)carbonyl)formazan 1,5-bis(2-methoxy-4-nitro-5-sulfophenyl)-3-((phenylamino)carbonyl)formazan: structure given in first source	2.13	1	0
aureol aureol: from the Jamaican sponge Smenospongia aurea; structure in first source	2.11	1	0	coumestans
abscisic acid Abscisic Acid: Abscission-accelerating plant growth substance isolated from young cotton fruit, leaves of sycamore, birch, and other plants, and from potatoes, lemons, avocados, and other fruits.. (S)-2-trans-abscisic acid : A 2-trans-abscisic acid with (S)-configuration at the chiral centre.. (+)-abscisic acid : The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold.	7.95	4	0	2-trans-abscisic acid
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.15	1	0	cyanine dye; organic iodide salt	fluorochrome
gw-5074 [no description available]	2.44	2	0
ammonium sulfate Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.	2.35	2	0	ammonium salt; inorganic sulfate salt	fertilizer
bisabolol bisabolol: monocyclic sesquiterpene alcohol with strong bacteriocidal effects, especilly against M. Tuberc.; isolated from seed plant Populus tacamacaha; RN given refers to cpd without isomeric desigation	8.61	8	0
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid Fluvastatin: An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.. (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which both chiral centres have S configuration.. fluvastatin : A racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. An HMG-CoA reductase inhibitor, it is used (often as the corresponding sodium salt) to reduce triglycerides and LDL-cholesterol, and increase HDL-chloesterol, in the treatment of hyperlipidaemia.	2.68	3	0	(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
mevalonolactone mevalonolactone: RN given refers to unlabeled cpd without isomeric designation; structure. mevalonolactone : A racemate comprising equimolar amounts of (R)-mevalonolactone and (S)-mevalonolactone.	3.37	7	0	4-hydroxy-4-methyloxan-2-one	fungal metabolite; plant metabolite
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.01	1	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
dolichols Dolichols: A class of polyprenols which contain approximately 20 isoprene residues. Although considered ISOPRENOIDS, they terminate with an alpha-saturated isoprenoid group at the hydroxy end of the molecule.	4.59	8	0	polyterpene
1-oleoyl-2-acetylglycerol [no description available]	2	1	0	1,2-diglyceride
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2	1	0
manumycin manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source. manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.	1.99	1	0	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite
squalestatin 1 squalestatin 1: structure given in first source; inhibits both mammalian and fungal squalene synthetase; from fungus Phoma sp (Coelomycetes). zaragozic acid A : A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase.	3.26	6	0	acetate ester; cyclic ketal; oxabicycloalkane; polyketide; tertiary alcohol; tricarboxylic acid	EC 2.5.1.21 (squalene synthase) inhibitor; fungal metabolite
s-farnesylcysteine S-farnesylcysteine: structural component of Saccharomyces cerevisiae mating hormone a-factor. S-[(2E,6E)-farnesyl]-L-cysteine : An S-farnesyl-L-cysteine where the C=C double bonds at the 2- and 6-positions both have (E)-configuration.	3.5	8	0	amino acid zwitterion; S-farnesyl-L-cysteine; S-polyprenyl-L-cysteine zwitterion
n-acetyl-s-farnesylcysteine N-acetyl-S-farnesylcysteine: inhibits prenyl-cysteine carboxyl methyl transferases	2.91	4	0	sesquiterpenoid
thermozymocidin thermozymocidin: a serine palmitoyltransferase inhibitor; FTY720 is an analog	2.07	1	0	alpha-amino fatty acid; hydroxy monocarboxylic acid; non-proteinogenic alpha-amino acid; sphingoid	antifungal agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor; fungal metabolite; immunosuppressive agent
geranylfarnesol [no description available]	1.99	1	0	geranylfarnesol
pregna-4,17-diene-3,16-dione pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor	2.05	1	0	3-hydroxy steroid	androgen
farnesyl monophosphate [no description available]	1.99	1	0
bacteriochlorophylls Bacteriochlorophylls: Pyrrole containing pigments found in photosynthetic bacteria.	2.42	2	0
bafilomycin c1 bafilomycin C1: structure given in first source	2.17	1	0
nb 598 NB 598: decreases serum total & LDL-cholesterol levels; structure given in first source; inhibits squalene epoxidase	2.01	1	0
terpestacin terpestacin: structure given in first source; isolated from Arthrinium; inhibits syncytium (giant cell) formation	2.07	1	0	secondary alcohol
presqualene pyrophosphate [no description available]	2.36	2	0
cyclopren cyclopren: structure in first source	3.06	5	0
beta-escin [no description available]	1.98	1	0
borneol [no description available]	1.98	1	0	borneol
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2	1	0	aminobenzoic acid
staurosporine staurosporinium : Conjugate acid of staurosporine.	1.99	1	0	ammonium ion derivative
3-methyl-n-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide 3-methyl-N-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide: a LIMK2 inhibitor; structure in first source	2.07	1	0
hypericum Hypericum: Genus of perennial plants in the family CLUSIACEAE (sometimes classified as Hypericaceae). Herbal and homeopathic preparations are used for depression, neuralgias, and a variety of other conditions. Hypericum contains flavonoids; GLYCOSIDES; mucilage, TANNINS; volatile oils (OILS, ESSENTIAL), hypericin and hyperforin.. 6-formamidopenicillanic acid : A penicillanic acid having a (6R)-formamido substituent.	2.07	1	0	penicillanic acids
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	3.29	6	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
formazans Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.	2.13	1	0
ggti 298 GGTI 298: inhibits geranylgeranyltransferase-I; structure in first source	1.99	1	0	leucine derivative
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.06	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trien-1-yl]benzoic acid [no description available]	1.98	1	0	hydroxybenzoic acid
ggti 2147 [no description available]	2.46	2	0
zaragozic acid b zaragozic acid B: structure given in first source; a fungal metabolite	7.42	2	0
zeolites [no description available]	2.45	2	0
bms 187745 BMS 187745: structure given in first source	2.91	1	0
beta-bisabolene (S)-beta-bisabolene : A beta-bisabolene which has (1S)-configuration.. beta-bisabolene : A bisabolene that is cyclohexene substituted by a methyl group at position 1 and a 6-methylhepta-1,5-dien-2-yl group at position 4.	2.08	1	0	beta-bisabolene
stachybotrin c stachybotrin C: isolated from Stachybotrys parvispora; structure in first source	1.99	1	0
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.75	3	0
sclerotiamide sclerotiamide: related to the paraherquamides; isolated from the sclerotia of Aspergillus sclerotiorum; structure given in first source	2.07	1	0
alloaromadendrene alloaromadendrene: isolated from the volatile oil of the soft corals Clavularia viridis and Sarcophyton acutangulum; structure in first source	2.1	1	0
n-acetyl-s-geranylgeranyl-cysteine N-acetyl-S-geranylgeranyl-cysteine: a prenylcysteine analog	2.4	2	0	diterpenoid
avrainvillamide avrainvillamide: from Aspergillus sp.; structure in first source	2.07	1	0	1-benzopyran
caryolan-1-ol caryolan-1-ol: structure in first source	2.1	1	0
chatancin chatancin: structure in first source	2	1	0
viridiflorol viridiflorol: a strong feeding deterrent for the melaleuca weevil that retards larval development; structure in first source. viridiflorol : A carbotricyclic compound that is (1aS,4aR,7aR,7bR)-decahydro-1H-cyclopropa[e]azulene carrying four methyl substituents at positions 1, 1, 4 and 7 as well as a hydroxy substituent at position 4. It is a sesquiterpenoid isolated from several plant species and is a strong feeding deterrent for the melaleuca weevil that retards larval development.	2.1	1	0	carbotricyclic compound; sesquiterpenoid; tertiary alcohol	anti-inflammatory agent; antifeedant; antimycobacterial drug; plant metabolite; volatile oil component
phytosterols Phytosterols: A class of organic compounds known as sterols or STEROIDS derived from plants.. phytosterols : Sterols similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.	2.4	2	0
santalol santalol: combination of alpha and beta isomers	2.53	2	0
titanocene titanocene: C10-H10-Ti. titanocene : A bis(eta(5)-cyclopentadienyl)metal(II) having Ti(II) as the metal(II) species. The parent of the class of titanonocenes.	2.11	1	0
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.11	1	0
ants Ants: Insects of the family Formicidae, very common and widespread, probably the most successful of all the insect groups. All ants are social insects, and most colonies contain three castes, queens, males, and workers. Their habits are often very elaborate and a great many studies have been made of ant behavior. Ants produce a number of secretions that function in offense, defense, and communication. (From Borror, et al., An Introduction to the Study of Insects, 4th ed, p676)	2.88	4	0
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	8.56	9	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
notoamide b notoamide B: structure in first source	2.07	1	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	3.7	10	0	1,2-diacyl-sn-glycero-3-phosphocholine
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	2.64	3	0	chlorophyll; methyl ester	cofactor
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2.01	1	0	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	8.67	10	0
chitosan [no description available]	7.72	2	0
sodium hypochlorite Sodium Hypochlorite: It is used as an oxidizing and bleaching agent and as a disinfectant. (From Grant & Hackh's Chemical Dictionary, 5th ed). sodium hypochlorite : An inorganic sodium salt in which hypochlorite is the counterion. It is used as a bleaching and disinfecting agent and is commonly found in household bleach.	2.52	2	0	inorganic sodium salt	bleaching agent; disinfectant
methyl jasmonate [no description available]	2.49	2	0
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.02	1	0	BODIPY compound
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.31	1	0
glycolipids [no description available]	2.05	1	0
piperidines Piperidines: A family of hexahydropyridines.	2.42	2	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.05	1	0
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	7.89	3	0
vasoactive intestinal peptide Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).	2	1	0
retigeric acid b retigeric acid B: from a lichen, Lobaria kurokawae Yoshim; structure in first source	7.07	1	0
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	2.43	2	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.45	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
raltegravir [no description available]	2.06	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.06	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.31	1	0
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	13.29	157	5	monohydroxybenzoate	plant metabolite
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.1	5	0	benzenes; hydroxycoumarin; methyl ketone
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	3.51	8	0
clay Clay: A naturally-occurring rock or soil constituent characterized by particles with a diameter of less than 0.005 mm. It is composed primarily of hydrous aluminum silicates, trace amounts of metal OXIDES, and organic matter.	2.25	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.96	4	0
staphyloxanthin staphyloxanthin: Staph aureus pigment; glucose esterified with both a triterpenoid carotenoid carboxylic acid & a C15 fatty acid. staphyloxanthin : A xanthophyll that is beta-D-glucopyranose in which the hydroxy groups at positions 1 and 6 have been acylated by an all-trans-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaenoyl group and a 12-methyltetradecanoyl group, respectively. Staphyloxanthin is responsible for the characteristic yellow-golden colour which gives the bacterium Staphylococcus aureus its name.	2.49	2	0	apo carotenoid triterpenoid; D-aldohexose derivative; fatty acid ester; triol; xanthophyll	antioxidant; biological pigment; metabolite; virulence factor
pyrethrins [no description available]	2.9	2	0
gsk2879552 GSK2879552: inhibits lysine demethylase 1; structure in first source. GSK2879552 : A member of the class of piperidines that is piperidine substituted by (4-carboxyphenyl)methyl and {[(1R,2S)-2-phenylcyclopropyl]amino}methyl groups at positions 1 and 4, respectively. It is a potent and irreversible inhibitor of lysine specific demethylase 1 (LSD1, also known as KDM1A). It was under clinical investigation for the treatment of acute myeloid leukaemia and small cell lung carcinoma.	3.23	1	0	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor
fti 277 FTI 277: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; blocks Ras oncogenic signaling by accumulating Ras/Raf complexes in the cytoplasm; structure given in first source	2.69	3	0
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	2.63	2	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	3.31	6	0
alcohol oxidase [no description available]	7	1	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	1.94	1	0
ggti 297 GGTI 297: inhibitor of farnesyltransferase; structure in first source	1.99	1	0
epoxyhomofarnesyl diazoacetate [no description available]	3.25	6	0
allatotropin allatotropin: from cerebral or corpora cardiaca of locusts & moths	2.01	1	0
rhodotorucine a rhodotorucine A: structure	4.15	5	0
gibberellins [no description available]	3.04	1	0
as 1411 AGRO 100: an antineoplastic agent that inhibits nuclear factor-kappaB activation; base sequence in first source	2.49	2	0
cytochalasin d Cytochalasin D: A fungal metabolite that blocks cytoplasmic cleavage by blocking formation of contractile microfilament structures resulting in multinucleated cell formation, reversible inhibition of cell movement, and the induction of cellular extrusion. Additional reported effects include the inhibition of actin polymerization, DNA synthesis, sperm motility, glucose transport, thyroid secretion, and growth hormone release.. cytochalasin D : An organic heterotricyclic compound that is a mycotoxin produced by Helminthosporium and other moulds which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis.	2.41	2	0
digitonin Digitonin: A glycoside obtained from Digitalis purpurea; the aglycone is digitogenin which is bound to five sugars. Digitonin solubilizes lipids, especially in membranes and is used as a tool in cellular biochemistry, and reagent for precipitating cholesterol. It has no cardiac effects.. digitonin : A spirostanyl glycoside that is digitogenin in which the 3-hydroxy group is substituted by a beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->3)]-beta-D-glucopyranosyl-(1->4)-beta-D-galactopyranosyl group. It is a steroidal saponin isolated from the foxglove plant, Digitalis purpurea. It is used extensively as a mild non-ionic detergent for extracting proteins from membranes for structure and function studies.	1.98	1	0
bixin bixin: structure. bixin : A carotenoic acid that is the 6'-monomethyl ester of 9'-cis-6,6'-diapocarotene-6,6'-dioic acid.	2.06	1	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.4	2	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	3.39	7	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	2.39	2	0	nucleoside triphosphate analogue
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.47	2	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.01	1	0	dacarbazine
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.02	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
prodigiosin Prodigiosin: 4-Methoxy-5-((5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl)- 2,2'-bi-1H-pyrrole. A toxic, bright red tripyrrole pigment from Serratia marcescens and others. It has antibacterial, anticoccidial, antimalarial, and antifungal activities, but is used mainly as a biochemical tool.. prodigiosin : A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens.	7.31	1	0
cholestyramine resin Cholestyramine Resin: A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.	1.95	1	0
eye [no description available]	1.98	1	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.02	1	0
yo-pro 1 YO-PRO 1: a generally membrane impermeable fluorescent dye	2.05	1	0
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	1.95	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.01	1	0

Condition	Relationship Strength	Studies	Trials
Acne [description not available]	1.98	1	0
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	1.98	1	0
Caries, Dental [description not available]	3.8	10	0
Dental Caries Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp.	8.8	10	0
Tuberculosis, Drug-Resistant [description not available]	2.1	1	0
Koch's Disease [description not available]	2.1	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.1	1	0
Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.	2.1	1	0
Cancer of Pancreas [description not available]	7.13	12	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	7.13	12	1
Benign Neoplasms [description not available]	9.04	20	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	9.04	20	2
Anemia, Fanconi [description not available]	2.13	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	6.83	37	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Hepatocellular Carcinoma [description not available]	3.81	10	0
Innate Inflammatory Response [description not available]	5.67	17	0
Cancer of Liver [description not available]	4.92	13	0
Experimental Hepatoma [description not available]	2.78	3	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.81	10	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	5.67	17	0
Liver Neoplasms Tumors or cancer of the LIVER.	4.92	13	0
Dermatoses [description not available]	2.31	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.31	1	0
Candida Infection [description not available]	5.66	17	0
Moniliasis, Oral [description not available]	2.76	3	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	5.66	17	0
Candidiasis, Oral Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)	2.76	3	0
Cirrhosis [description not available]	2.53	2	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.53	2	0
Breast Cancer [description not available]	4.09	14	0
Breast Neoplasms Tumors or cancer of the human BREAST.	4.09	14	0
Diathesis [description not available]	2.31	1	0
Atrophy, Muscular, Peroneal [description not available]	2.31	1	0
Clinically Isolated CNS Demyelinating Syndrome [description not available]	2.52	2	0
Charcot-Marie-Tooth Disease A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)	7.31	1	0
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	2.52	2	0
Adenocarcinoma, Basal Cell [description not available]	6.16	6	2
Cancer of Colon [description not available]	3.14	5	0
Cancer of Lung [description not available]	5.16	10	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	6.16	6	2
Colonic Neoplasms Tumors or cancer of the COLON.	3.14	5	0
Lung Neoplasms Tumors or cancer of the LUNG.	5.16	10	1
Demineralization, Tooth [description not available]	2.41	1	0
2019 Novel Coronavirus Disease [description not available]	2.41	1	0
Infections, Staphylococcal [description not available]	3.21	5	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	3.21	5	0
Aura [description not available]	2.41	1	0
Absence Seizure [description not available]	2.41	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.41	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	7.41	1	0
Fatty Liver, Nonalcoholic [description not available]	2.69	2	0
Insulin Sensitivity [description not available]	3.46	2	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	3.46	2	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.54	2	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.69	2	0
Cardiac Toxicity [description not available]	3.33	4	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	3.33	4	0
Infections, Plasmodium [description not available]	3.01	2	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	3.01	2	0
Cognitive Decline [description not available]	2.6	1	0
Inadequate Sleep [description not available]	2.6	1	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.6	1	0
Candidiasis, Genital [description not available]	2.72	2	0
Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.	2.72	2	0
Acute Liver Injury, Drug-Induced [description not available]	2.6	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	7.82	3	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.6	1	0
Leishmaniasis, American [description not available]	2.6	1	0
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	2.6	1	0
Muscular Weakness [description not available]	2.6	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.6	1	0
Muscle Weakness A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)	7.6	1	0
Allergic Encephalomyelitis [description not available]	3.93	4	0
MS (Multiple Sclerosis) [description not available]	2.6	1	0
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.6	1	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	2.6	1	0
Leishmania Infection [description not available]	2.6	1	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	2.6	1	0
Carcinoma, Non-Small Cell Lung [description not available]	4.17	3	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	4.17	3	1
Acute Confusional Senile Dementia [description not available]	2.21	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.21	1	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.25	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.25	1	0
Carcinoma, Ductal, Pancreatic [description not available]	2.31	1	0
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.31	1	0
Bradyarrhythmia [description not available]	2.31	1	0
Blood Pressure, High [description not available]	4.07	3	1
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	2.31	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	4.07	3	1
Benign Neoplasms, Brain [description not available]	3.33	6	0
Astrocytoma, Grade IV [description not available]	3.44	7	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	3.33	6	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	3.44	7	0
Cancer of Prostate [description not available]	3.42	7	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.42	7	0
Sunburn An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.	7.61	2	0
Bladder Cancer [description not available]	2.17	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.17	1	0
Allotriophagy An unusual desire or craving for abnormal foods.	2.17	1	0
Emesis [description not available]	2.17	1	0
Weight Reduction [description not available]	2.17	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	2.17	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	2.17	1	0
Weight Loss Decrease in existing BODY WEIGHT.	2.17	1	0
Allergic Contact Dermatitis [description not available]	4.33	7	0
Facial Dermatoses Skin diseases involving the FACE.	2.47	2	0
Dermatitis, Occupational A recurrent contact dermatitis caused by substances found in the work place.	2.48	2	0
Hand Dermatosis [description not available]	2.74	3	0
Leg Dermatoses A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)	2.21	1	0
Hand Dermatoses Skin diseases involving the HANDS.	2.74	3	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	4.33	7	0
Disseminated Trichosporonosis [description not available]	2.21	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	7.21	1	0
Left Ventricular Dysfunction [description not available]	2.21	1	0
Arrhythmia [description not available]	7.21	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.21	1	0
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	2.21	1	0
Skin Aging The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.	2.25	1	0
Autoimmune Disease [description not available]	3.35	2	0
Diabetes Mellitus, Adult-Onset [description not available]	4.31	2	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	3.35	2	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	4.31	2	0
Neoplasms, Nerve Sheath [description not available]	2.46	2	0
Nerve Sheath Neoplasms Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.	2.46	2	0
Cancer of Endometrium [description not available]	2.08	1	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.08	1	0
Bone Loss, Osteoclastic [description not available]	2.73	3	0
Carcinoma, Anaplastic [description not available]	2.43	2	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.43	2	0
Injury, Myocardial Reperfusion [description not available]	2.72	3	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.08	1	0
Adjuvant Arthritis [description not available]	2.44	2	0
Rheumatoid Arthritis [description not available]	2.38	2	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.38	2	0
HIV Coinfection [description not available]	3.19	5	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.19	5	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	3.29	6	0
Invasiveness, Neoplasm [description not available]	2.52	2	0
Chronic Lung Injury [description not available]	2.76	3	0
Edema, Pulmonary [description not available]	2.1	1	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.1	1	0
Extravascular Hemolysis [description not available]	2.1	1	0
Experimental Mammary Neoplasms [description not available]	2.76	3	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.1	1	0
Recrudescence [description not available]	2.11	1	0
Bisphosphonate Osteonecrosis [description not available]	2.52	2	0
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	2.43	2	0
Acute Necrotizing Pancreatitis [description not available]	2.11	1	0
Lymphangiomyomatosis [description not available]	2.49	2	0
Lymphangioleiomyomatosis A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).	2.49	2	0
Angiomyolipoma A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)	2.1	1	0
Sporothrix brasiliensis Infection [description not available]	2.11	1	0
Sporotrichosis The commonest and least serious of the deep mycoses, characterized by nodular lesions of the cutaneous and subcutaneous tissues. It is caused by inhalation of contaminated dust or by infection of a wound with SPOROTHRIX.	2.11	1	0
Experimental Neoplasms [description not available]	2.68	3	0
Kahler Disease [description not available]	2.72	3	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	7.72	3	0
Leucocythaemia [description not available]	4.48	5	1
Local Neoplasm Recurrence [description not available]	3.5	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	4.48	5	1
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.13	1	0
Carcinoma, Epidermoid [description not available]	2.73	3	0
Cancer of Esophagus [description not available]	2.13	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.73	3	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.13	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.11	1	0
Viremia The presence of viruses in the blood.	2.11	1	0
Fungal Diseases [description not available]	3.74	3	0
Mycoses Diseases caused by FUNGI.	3.74	3	0
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	2.11	1	0
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	2.11	1	0
Degenerative Diseases, Central Nervous System [description not available]	2.46	2	0
Astrocytosis [description not available]	2.11	1	0
Dyskinesia Syndromes [description not available]	2.11	1	0
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	2.11	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.46	2	0
Aspergillus Infection [description not available]	2.11	1	0
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	2.11	1	0
Ewing Sarcoma [description not available]	2.11	1	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	2.11	1	0
Dental Plaque A film that attaches to teeth, often causing DENTAL CARIES and GINGIVITIS. It is composed of MUCINS, secreted from salivary glands, and microorganisms.	3.67	3	0
Burkholderia pseudomallei Infection [description not available]	2.13	1	0
Candidemia A form of invasive candidiasis where species of CANDIDA are present in the blood.	2.53	2	0
Bone Cancer [description not available]	2.47	2	0
Age-Related Osteoporosis [description not available]	2.51	2	0
Osteogenic Sarcoma [description not available]	2.47	2	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.47	2	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.51	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.47	2	0
Benign Meningeal Neoplasms [description not available]	2.15	1	0
Angioblastic Meningioma [description not available]	2.52	2	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	2.15	1	0
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	2.52	2	0
Co-infection [description not available]	3.04	1	0
Bacterial Infections, Gram-Negative [description not available]	3.04	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	3.04	1	0
Colorectal Cancer [description not available]	2.5	2	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.5	2	0
Vulvovaginitis Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS.	7.13	1	0
Biliary Cirrhosis [description not available]	2.15	1	0
Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.	2.15	1	0
Cystic Fibrosis of Pancreas [description not available]	2.15	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.15	1	0
Bacterial Disease [description not available]	2.04	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	2.04	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	5.93	14	2
Broad Beta Disease [description not available]	2.96	1	0
Hyperlipoproteinemia Type III An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.	2.96	1	0
Cancer of the Tongue [description not available]	2.04	1	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	2.04	1	0
Anasarca [description not available]	4.07	3	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	9.07	3	1
P carinii Infection [description not available]	2.05	1	0
Pneumocystis Infections Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.	2.05	1	0
Disease Exacerbation [description not available]	2.05	1	0
Atherogenesis [description not available]	2.45	2	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.45	2	0
Elevated Cholesterol [description not available]	2.9	4	0
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	2.9	4	0
Cancer of Skin [description not available]	2.71	3	0
Skin Neoplasms Tumors or cancer of the SKIN.	2.71	3	0
Germinoblastoma [description not available]	3.44	1	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	3.44	1	1
Autoimmune Diabetes [description not available]	2.05	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.05	1	0
Sterility, Male [description not available]	2.05	1	0
Infertility, Male The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.	2.05	1	0
Liver Steatosis [description not available]	2.05	1	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	2.05	1	0
Carcinoma, Oat Cell [description not available]	2.06	1	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.06	1	0
Cancer of the Thyroid [description not available]	2.05	1	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.05	1	0
Infections, Legionella pneumophila [description not available]	2.05	1	0
Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.	2.05	1	0
Anisakiasis Infection with roundworms of the genus ANISAKIS. Human infection results from the consumption of fish harboring roundworm larvae. The worms may cause acute NAUSEA; VOMITING; or penetrate into the wall of the DIGESTIVE TRACT where they give rise to EOSINOPHILIC GRANULOMA in the STOMACH; INTESTINES; or the OMENTUM.	2.06	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.12	5	0
Muscular Dystrophy [description not available]	2.06	1	0
Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.	2.06	1	0
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	2.37	2	0
Candidiasis, Invasive An important nosocomial fungal infection with species of the genus CANDIDA, most frequently CANDIDA ALBICANS. Invasive candidiasis occurs when candidiasis goes beyond a superficial infection and manifests as CANDIDEMIA, deep tissue infection, or disseminated disease with deep organ involvement.	2.99	1	0
Neurilemoma [description not available]	2.06	1	0
Neurilemmoma A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)	2.06	1	0
Catheter-Associated Infections [description not available]	2.06	1	0
Alloxan Diabetes [description not available]	2.06	1	0
Diseases, Metabolic [description not available]	2.06	1	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.06	1	0
Angiogenesis, Pathologic [description not available]	2.07	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.07	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.07	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.07	1	0
Glial Cell Tumors [description not available]	2.93	4	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.93	4	0
Nerve Pain [description not available]	2.07	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.07	1	0
Acute Brain Injuries [description not available]	2.73	3	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.73	3	0
Acute Lymphoid Leukemia [description not available]	2.07	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.07	1	0
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	2.99	1	0
C gattii Infection [description not available]	2.07	1	0
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	2.07	1	0
Eczema, Atopic [description not available]	4.1	3	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	4.1	3	1
Granulocytic Leukemia [description not available]	2.4	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.4	2	0
Chronic Illness [description not available]	3.76	2	1
Lesion of Sciatic Nerve [description not available]	2.01	1	0
Ankle Injuries Harm or hurt to the ankle or ankle joint usually inflicted by an external source.	2.01	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.76	2	1
Hypergammaglobulinemia An excess of GAMMA-GLOBULINS in the serum due to chronic infections or PARAPROTEINEMIAS.	2.01	1	0
Benign Paroxysmal Peritonitis [description not available]	3.33	2	0
Familial Mediterranean Fever A group of HEREDITARY AUTOINFLAMMATION DISEASES, characterized by recurrent fever, abdominal pain, headache, rash, PLEURISY; and ARTHRITIS. ORCHITIS; benign MENINGITIS; and AMYLOIDOSIS may also occur. Homozygous or compound heterozygous mutations in marenostrin gene encoding PYRIN result in autosomal recessive transmission; simple heterozygous, autosomal dominant form of the disease also exists with mutations in the same gene.	3.33	2	0
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	2.01	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	4.68	11	0
Dental Deposit [description not available]	2.01	1	0
Condition, Preneoplastic [description not available]	2.01	1	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	2.01	1	0
B16 Melanoma [description not available]	2.7	3	0
Anti-Phospholipid Antibody Syndrome [description not available]	2.71	3	0
Antiphospholipid Syndrome The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).	2.71	3	0
Nephritis Inflammation of any part of the KIDNEY.	2.01	1	0
Malignant Melanoma [description not available]	2.67	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.67	3	0
Closed Head Injuries [description not available]	2.42	2	0
Symptom Cluster [description not available]	2.93	1	0
Syndrome A characteristic symptom complex.	2.93	1	0
Hyperlipemia [description not available]	2.01	1	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.01	1	0
Gastroduodenal Ulcer [description not available]	3.44	8	0
Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	3.44	8	0
Carotid Arteriopathies, Traumatic [description not available]	2.02	1	0
Plasmodium falciparum Malaria [description not available]	2.02	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.02	1	0
Akinetic-Rigid Variant of Huntington Disease [description not available]	2.02	1	0
Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)	2.02	1	0
Cirrhoses, Experimental Liver [description not available]	2.41	2	0
Allergic Neuritis, Experimental [description not available]	2.02	1	0
Hormone-Dependent Neoplasms [description not available]	2.03	1	0
Abnormalities, Autosome [description not available]	2.4	2	0
Mouth Diseases Diseases involving the MOUTH.	2.03	1	0
Cafe-au-Lait Spots with Pulmonic Stenosis [description not available]	2.03	1	0
Neurofibromatosis 1 An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).	2.03	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.03	1	0
Day Blindness [description not available]	2.04	1	0
Hyper IgD Syndrome [description not available]	2.04	1	0
Mevalonate Kinase Deficiency Autosomal recessive disorder caused by mutations in the mevalonate kinase gene. Because of the mutations cholesterol biosynthesis is disrupted and MEVALONIC ACID accumulates. It is characterized by a range of symptoms, including dysmorphic FACIES, psychomotor retardation, CATARACT, hepatosplenomegaly, CEREBELLAR ATAXIA, elevated IMMUNOGLOBULIN D, and recurrent febrile crises with FEVER; LYMPHADENOPATHY; ARTHRALGIA; EDEMA; and rash.	2.04	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.04	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	2.4	2	0
Acute Disease Disease having a short and relatively severe course.	1.98	1	0
Coronary Heart Disease [description not available]	1.98	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	1.98	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	4.61	10	0
Dysmyelopoietic Syndromes [description not available]	1.99	1	0
Granulocytic Leukemia, Chronic [description not available]	1.99	1	0
Acute Promyelocytic Leukemia [description not available]	2.4	2	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	1.99	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	1.99	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.4	2	0
Adenoma, Prostatic [description not available]	1.99	1	0
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	1.99	1	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	1.99	1	0
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.4	2	0
Anoxemia [description not available]	2	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2	1	0
Merkel Cell Cancer [description not available]	2	1	0
Carcinoma, Merkel Cell A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)	2	1	0
Acute Myelogenous Leukemia [description not available]	2	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2	1	0
Cataract, Membranous [description not available]	2	1	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	2	1	0
Injury, Ischemia-Reperfusion [description not available]	2	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2	1	0
Palsy [description not available]	2	1	0
Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)	2	1	0
Libman-Sacks Disease [description not available]	2.37	2	0
Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.	2	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.37	2	0
Starvation Lengthy and continuous deprivation of food. (Stedman, 25th ed)	1.95	1	0
Anochlesia [description not available]	1.95	1	0
Delayed Effects, Prenatal Exposure [description not available]	2.67	3	0
Dermatitis, Contact, Phototoxic [description not available]	1.98	1	0
Contact Dermatitis [description not available]	1.98	1	0
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	1.98	1	0
ATLL [description not available]	1.98	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	1.98	1	0
Di Guglielmo Disease [description not available]	1.97	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	1.97	1	0
Black Death [description not available]	1.96	1	0
Plague An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.	1.96	1	0
Curling Ulcer Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.	4.02	3	1
Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM.	4.02	3	1
Deficiency, Vitamin K [description not available]	1.94	1	0
Vitamin K Deficiency A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)	1.94	1	0
Gastric Ulcer [description not available]	4.58	3	2
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	4.58	3	2
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	3.33	1	1
Enteritis Inflammation of any segment of the SMALL INTESTINE.	1.95	1	0
Hymenolepiasis Infection with tapeworms of the genus Hymenolepis.	1.95	1	0
Colitis Gravis [description not available]	1.94	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	1.94	1	0
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	1.94	1	0
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	1.94	1	0
Reproductive Sterility [description not available]	1.94	1	0
Infertility A reduced or absent capacity to reproduce.	1.94	1	0
Hives [description not available]	1.94	1	0
Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.	1.94	1	0
Infantile Diarrhea [description not available]	1.94	1	0
Diarrhea, Infantile DIARRHEA occurring in infants from newborn to 24-months old.	1.94	1	0

farnesol

Description

Cross-References

Synonyms (121)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (3 Product(s))

Product Categories

Products

Roles (1)

Drug Classes (1)

Pathways (6)

Protein Targets (47)

Potency Measurements

Inhibition Measurements

Biological Processes (159)

Molecular Functions (46)

Ceullar Components (29)

Bioassays (859)

Research

Studies (1,118)

Study Types

farnesol

Description

Related Flora

Cross-References

Synonyms (121)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (3 Product(s))

Product Categories

Products

Roles (1)

Drug Classes (1)

Pathways (6)

Protein Targets (47)

Potency Measurements

Inhibition Measurements

Biological Processes (159)

Molecular Functions (46)

Ceullar Components (29)

Bioassays (859)

Research

Studies (1,118)

Study Types

Related Drugs (672)

Related Conditions (372)